8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 8 8 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Financial review The following review should be read in conjunction with the consolidated Substantially all of the Groups revenues, expenditures and net assets financial statements and related Notes on pages 70 to 121 of this are attributable to the research and development R&D, manufacture, Annual Report.
sale and distribution of pharmaceutical products within two reportable segments: Specialty Pharmaceuticals SP and HGT.
The Group also Overview earns royalties where Shire has out-licensed products to third-parties Shires strategic goal is to be the leading specialty biopharmaceutical which are recorded as revenues.
company in the world that focuses on meeting the needs of the specialist physician.
Shire focuses its business on ADHD, Human Revenues are derived primarily from two sourcessales of the Groups Genetic Therapies HGT and GI diseases, as well as opportunities own products and royalties: in other specialty therapeutic areas to the extent they arise through 90% 2009: 90% of total revenues are derived from product sales, acquisitions.
Shires in-licensing, merger and acquisition efforts are of which 71% 2009: 79% are within SP and 29% 2009: 21% are focused on products in specialist markets with strong intellectual within HGT: and property protection and global rights.
Shire believes that a carefully selected and balanced portfolio of products with strategically aligned9% of total revenues are derived from royalties 2009: 9%.
and relatively small-scale sales forces will deliver strong results.
Currently marketed products The table below lists the Groups material marketed products at December 31, 2010 indicating the owner licensor, disease area and the key territories in which Shire markets the product.
SPECIALTY PHARMACEUTICALS Products Disease area Owner licensor Key territories Treatments for ADHD 1 VYVANSE lisdexamfetamine dimesylate ADHD Shire US and Canada INTUNIV extended release guanfacine ADHD Shire US 2 EQUASYM methylphenidate hydrochloride ADHD Shire Europe and Latin America immediate release IR and modified release XL ADDERALL XR mixed salts of a single-entity amphetamine ADHD Shire US and Canada Treatments for GI diseases 3 LIALDA mesalamine MEZAVANT mesalazine Ulcerative colitis Giuliani SpA US and Europe PENTASA mesalamine Ulcerative colitis Shire US RESOLOR prucalopride Chronic constipation Shire Europe in women Treatments for diseases in other therapeutic areas 2,4 FOSRENOL lanthanum carbonate Hyperphosphatemia in end Shire US, Europe and Japan stage renal disease CALCICHEW calcium carbonate range Adjunct in osteoporosis Nycomed Pharma UK and Republic of Ireland AS Nycomed CARBATROL carbamazepine extended-release capsules Epilepsy Shire US 5 REMINYL REMINYL XL galantamine hydrobromide Alzheimers disease Synaptech, Inc. UK and Republic of Ireland Synaptech 2 XAGRID anagrelide hydrochloride Elevated platelet counts Shire Europe in at risk essential thrombocythemia patients 1 Approval in Brazil was granted in July 2010: the product will be marketed as VENVANSE in Brazil.
2 Marketed by distributors in certain markets.
3 Marketed in US as LIALDA and Europe as MEZAVANT XL or MEZAVANT.
4 Marketed in Japan under license by Bayer Yakuhin Limited Bayer.
5 Marketed in rest of world RoW under license from Shire by Janssen Pharmaceutica N. V. Janssen part of the J&J group of companies.
Review of our business 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 9 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 9 HUMAN GENETIC THERAPIES Products Disease area Owner licensor Key territories REPLAGAL agalsidase alfa Fabry disease Shire Europe, Latin America 1 and Asia Pacific ELAPRASE idursulfase Hunter syndrome Shire US, Europe, Latin America 2  and Asia Pacific Type II, MPS II FIRAZYR icatibant Hereditary angioedema Shire Europe and Latin America HAE VPRIV velaglucerase alfa Gaucher disease, type 1 Shire US, Europe and Latin America 1 Marketed in Japan under license from Shire by Dainippon Sumitomo Pharma Co. Ltd. DSP.
2 Marketed in Asia Pacific by Genzyme under license from Shire.
Royalties received from other products ANTIVIRAL PRODUCTS Products Principal indications Relevant territory marketed by 1 3TC EPIVIR lamivudine Human Immunodeficiency Virus HIV Canada Shire and ViiV : RoW ViiV COMBIVIR lamivudine and zidovudine HIV Canada Shire and ViiV: RoW ViiV TRIZIVIR lamivudine, zidovudine and abacavir HIV Canada Shire and ViiV: RoW ViiV EPZICOM KIVEXA lamivudine and abacavir HIV Canada Shire and ViiV: RoW ViiV 2 ZEFFIX EPIVIR-HBV HEPTOVIR lamivudine Hepatitis B infection Canada Shire and GSK: RoW GSK 1 In 1996 Shire formed a commercialization partnership with GSK to market 3TC and Zeffix in Canada.
In 2009 GSK assigned its interest in the partnership to ViiV.
2 This is not a comprehensive list of trademarks for this product.
The product is also marketed under other trademarks in some markets.
OTHER PRODUCTS Manufacturing and distribution Active pharmaceutical ingredient API sourcing ADDERALL XR The Group sources API from third-party suppliers for its SP products Shire receives royalties from Impax Laboratories, Inc. sales of and its HGT product FIRAZYR.
Shire has manufacturing capability authorized generic ADDERALL XR.
for agalsidase alfa, idursulfase and velaglucerase alfa at its protein manufacturing plant in Cambridge, Massachusetts, US for its HGT REMINYL and REMINYL XL products, REPLAGAL, ELAPRASE and VPRIV.
Shire receives royalties, outside of the UK and Republic of Ireland, on Janssens sales of REMINYL and REMINYL XL under the name The Group currently has a dual source of API for VYVANSE, RAZADYNE and RAZADYNE ER in the US.
ADDERALL XR and PENTASA and is developing dual sources for LIALDA and INTUNIV.
The Group manages the risks associated with FOSRENOL reliance on single sources of API by carrying additional inventories Shire licensed the rights to FOSRENOL in Japan to Bayer in December or developing second sources of supply.
Bayer launched FOSRENOL in Japan in March 2009.
Shire receives royalties from Bayers sales of FOSRENOL in Japan.
In order to support the rapid growth of VPRIV and REPLAGAL, as well as to support clinical development, additional manufacturing capacity has been added in Lexington, Massachusetts, US.
Validation runs for REPLAGAL have been completed and submissions to support approval of the new facility will occur in the first half of 2011.
VPRIV validation runs will be completed in 2011 with submission in late 2011.
Finished product manufacturing The Group sources most of its SP products from third-party contract manufacturers.
HGT finished products are manufactured by contract manufacturers specializing in aseptic fill-finish operations.
8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 10 10 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Financial review The Group currently has dual sources for VYVANSE, ELAPRASE and In the regular course of business, the Groups patents may be REPLAGAL and is developing a second source for the manufacturing challenged by third-parties.
The Group is a party to litigation or other of LIALDA.
The Group sources ADDERALL XR, FOSRENOL, FIRAZYR, proceedings relating to intellectual property rights.
Details of ongoing INTUNIV, CARBATROL, PENTASA, VPRIV, RESOLOR and XAGRID litigation are provided in Note 20 Commitments and contingencies from a single contract manufacturer for each product.
The Group to the consolidated financial statements.
manages the risks associated with reliance on single sources of production by carrying additional inventories.
The degree of patent protection afforded to pharmaceutical inventions around the world is uncertain.
If patents are granted to other parties During 2009, following a comprehensive evaluation of its operations that contain claims having a scope that is interpreted by the relevant and strategic focus, Shire decided to phase out operations at its authorities to cover any of the Groups products or technologies, there SP manufacturing facility at Owings Mills, Maryland.
Over 2011, all can be no guarantee that the Group will be able to obtain licenses to products currently manufactured by Shire at this site will transition such patents or make other arrangements at reasonable cost, if at all.
to a contract manufacturer and operations and employee numbers will wind down over this period.
The existence, scope and duration of patent protection varies among the Groups products and among the different countries where the Distribution Groups products may be sold.
They may also change over the course The Groups US distribution center for SP products, which includes of time as patents are granted or expire, or become extended, a large vault to house US Drug Enforcement Administration DEA modified or revoked.
regulated Schedule II products, is located in Kentucky.
From there, the Group primarily distributes its products through the three major The loss of patent protection following a legal challenge may result wholesalers who have hub or distribution centers that stock Schedule II in third-parties commencing commercial sales of their own versions drugs in the US, providing access to nearly all pharmacies in the US.
of the Groups products before the expiry of the patents.
The Groups sales of such product s may decrease in consequence.
In many The distribution and warehousing of HGT products for the US market cases, however, the Groups products have more than one patent is contracted out to specialist third-party contractors.
In such cases, or where the Group enjoys trade secrets, manufacturing expertise, patient preference or regulatory Outside of the US, physical distribution of SP and HGT products exclusivity, the Group may continue to market its own products without is either contracted out to third-parties where the Group has local its commercial sales of those products being adversely affected by operations or facilitated via distribution agreements where the Group the loss of any given patent.
does not have local operations.
Competition Material customers Shire believes that competition in its markets is based on, among other The Groups two largest trade customers are Cardinal Health, Inc. and things, product safety, efficacy, convenience of dosing, reliability, McKesson Corp. both of which are in the US.
In 2010, these wholesale availability and price.
Companies with more resources and larger R&D customers accounted for approximately 25% and 19% of product expenditures than Shire have a greater ability to fund the research and sales, respectively.
clinical trials necessary for regulatory applications, and consequently may have a better chance of obtaining approval of drugs that would Intellectual property then compete with Shires products.
Other products now in use or An important part of the Groups business strategy is to protect its being developed by others may be more effective or have fewer sideproducts and technologies through the use of patents and trademarks, effects than the Groups current or future products.
The market share to the extent available.
The Group also relies on trade secrets, data provided below is sourced from IMS Health.
unpatented know-how, technological innovations and contractual arrangements with third-parties to maintain and enhance its ADHD market competitive position where it is unable to obtain patent protection Competition in the US ADHD market has increased with the launch of or where marketed products are not covered by specific patents.
competing products in recent years, including the launch of authorized The Groups commercial success will depend, in part, upon its ability generic versions of ADDERALL XR by Teva Pharmaceutical Industries, to obtain and enforce strong patents, to maintain trade secret Ltd. Teva and Impax Laboratories, Inc. Impax in 2009.
This protection, to operate without infringing the proprietary rights of others genericization has resulted in a decline in sales of ADDERALL XR and and to comply with the terms of licenses granted to it.
The Groups in December 2010 authorized generic versions of ADDERALL XR policy is to seek patent protection for proprietary technology whenever had a 12.4% share of the US ADHD market.
In late 2010, KAPVAY possible in the US, Canada, major European countries and Japan.
clonidine extended release was approved by the US Food and Drug Where practicable, the Group seeks patent protection in other Administration FDA for the treatment of ADHD and is being launched countries on a selective basis.
In all cases the Group endeavors to in the US by Shionogi & Co. Ltd in early 2011.
Shires share of the US either obtain patent protection itself or support patent applications by ADHD market in December 2010 was 24.6% compared to 22% in its licensors.
The markets for some of the potential products for rare December 2009, excluding DAYTRANA which the Group divested to genetic diseases caused by protein deficiencies are small, and, where Noven in October 2010. possible, the Group has sought orphan drug designation for products directed to these markets.
Review of our business 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 11 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 11 Shires key ADHD market is the US with three products for the GI treatment of ADHD.
Shire also has ADHD products in Canadian and selected European Union EU markets and further geographic Ulcerative Colitis market expansion plans are underway.
Ulcerative colitis is a type of Inflammatory Bowel Disease.
The primary treatments for patients with ulcerative colitis are formulations containing VYVANSE, a long-acting pro-drug stimulant designed to provide mesalamine also known as 5-ASA.
More than 88% of all ulcerative once-daily dosing, approved for the treatment of ADHD in children, colitis patients receive treatment with 5-ASA.
In 2009, Salix launched adolescents, and adults, and launched in 2007 in the US and for APRISO and Proctor and Gamble launched ASACOL HD.
Proctor and children in Canada in 2010.
Launches in Brazil and selected EU Gamble subsequently sold the ASACOL franchise to Warner Chilcott.
markets are planned for 2011 and beginning in 2012, respectively, At December 31, 2010 APRISO and ASACOL HD had 5.7% and 9.1% subject to receiving the requisite governmental or regulatory market share, respectively.
Shire defines the 5-ASA competitive set as approvals: the non-sulfasalazine, oral mesalamine and mesalamine pro-drug products.
In December 2010, Shires share of the US ulcerative colitis INTUNIV, a long-acting non-stimulant, non-scheduled treatment market was 34.3% compared to 32% in December 2009. for ADHD in children and adolescents, launched in November 2009 and planned for selected EU markets beginning in 2014, subject The US oral 5-ASA market is led by Warner-Chilcotts ASACOL.
to receiving the requisite governmental or regulatory approvals: In December 2010, ASACOL had a 42.4% share of the oral 5-ASA ADDERALL XR, an extended release stimulant, launched in the market, declining from 52.3% in December 2009.
In December US and Canada in 2001 and 2004, respectively: and 2010 Salixs COLAZAL had a 0.9% market share, while Alaven Pharmaceutical LLCs DIPENTUM had a 0.6% market share.
EQUASYM XL, a long-acting stimulant, methylphenidate capsules acquired from UCB in 2009 and launched in selected EU markets.
The EU oral 5-ASA market is somewhat more fragmented.
All market shares stated in this paragraph are as at November 2010.
Major Many products which compete with the Groups ADHD products competitors in the UK include Warner Chilcotts ASACOL which had in the US contain methylphenidate, including the following once-daily a 56% share of the UK oral 5-ASA market and Ferrings PENTASA, formulations: CONCERTA, launched in 2000 by J&J in conjunction which had a 25% share of the same market.
The German oral 5-ASA with Alza : METADATE CD, launched in 2001 by UCB: RITALIN LA, market is led by Dr Falks SALOFALK, with 56% market share, followed launched by Novartis in 2002: DAYTRANA launched in 2006 by Shire by Shires MEZAVANT with 17% share.
Merkle Recordati GmbHs and subsequently divested to Noven in October 2010, and FOCALIN CLAVERSAL has 15% share.
CLAVERSAL and Ferrings PENTASA XR, launched by Novartis in conjunction with Celgene Corporation in are the leaders in the oral 5-ASA market in Spain with 41% and 46% 2005.
In December, 2010, CONCERTA, METADATE CD, RITALIN LA, market shares respectively.
Ferrings PENTASA is the market leader in DAYTRANA, and FOCALIN XR had a 16.4%, 1.6%, 1.1%, 1.0% and France with 78% market share of the oral 5-ASA market.
Norgine B. V. s 5.8% share of the US ADHD market, respectively.
In 2003, Eli Lilly FIV-ASA had a 19% share of the French oral 5-ASA market.
Overall, launched STRATTERA, a non-stimulant, non-scheduled treatment for ASACOL had a 21% share of the EU G5 oral 5-ASA market UK, ADHD.
In December 2010, STRATTERA had a 5.3% share of the US Germany, Spain, Italy, and France.
In 2010, Ferring launched a new ADHD market.
key competitor, PENTASA 1gm tablet in the Netherlands, Denmark, Norway and Slovakia and we expect future EU launches in 2011.
Key competitors in the European ADHD market are CONCERTA Janssen-Cilag, RITALIN LA Novartis, MEDIKINET Medice and Mesalamine and balsalazide mesalamine pro-drug products are STRATTERA Eli Lilly, depending upon the country.
generally protected by formulation patents only.
In December 2007, the FDA denied Salixs Citizen Petition for COLAZAL and Salix The Group is also aware of clinical development efforts by AstraZeneca subsequently announced the launch of an authorized generic version plc in collaboration with Targacept, Inc., Eli Lilly and Company Limited, by Watson Laboratories.
This was followed by the introduction of three J&J, Merck & Co. Inc. Otsuka Pharmaceutical Co. Ltd. NextWave other generic versions of COLAZAL.
Generic versions of COLAZAL Pharmaceuticals, Inc. PsychoGenics, Inc. and Supernus to develop had a 6.9% share of the US oral 5-ASA market in December 2010. additional treatment options for ADHD.
The Group is aware of other 5-ASA and non-ASA biologic treatments in development for GI disorders by UCB, Abbott Laboratories and Centocor Ortho Biotech Inc.
Chronic constipation market In Europe over-the-counter and prescription laxatives are the current first line therapy for chronic constipation.
The highest value laxative by revenue is MOVICOL, a polyethylene glycol PEG 3350, sold by Norgine.
In Europe, RESOLOR is indicated for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.
Currently, there are no other products available to treat chronic constipation in patients who do not adequately respond to laxative treatment.
The Group is aware of other therapies for the treatment of chronic constipation being developed by Ironwood Pharmaceuticals, Inc. Forest Laboratories, Inc. Almirall, Synergy Pharmaceuticals, Inc. ARYx Therapeutics, Theravance, Inc. Sucampo Pharmaceuticals, Inc. and Albireo.
8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 12 12 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Financial review Markets for the treatment of rare genetic diseases The markets in which the Group conducts its business are highly Competitors for lysosomal storage disorder LSDs include Actelion competitive and highly regulated.
The healthcare industry is Ltd. Protalix BioTherapeutics Inc. Protalix, and Genzyme.
For experiencing: example, REPLAGAL competes with Genzymes FABRAZYME, and pressure from governments and healthcare providers to keep VPRIV competes with Genzymes CEREZYME, Actelions ZAVESCA prices low while increasing access to drugs: and will compete with the Protalix compound UPLYSO worldwide rights outside of Israel licensed to Pfizer if approved.
Shire is aware increased R&D costs, because development programs are of two companies Korea Green Cross Corporation and JCR typically larger and take longer to get approval from regulators: Pharmaceuticals Co. Ltd that are developing Enzyme Replacement challenges to existing patents from generic manufacturers: Therapies ERT for the treatment of Hunter syndrome.
governments and healthcare systems favoring earlier entry FIRAZYR competes in Europe with CSL Behrings BERINERT P, of low cost generic drugs: and a human plasma-derived C1-esterase inhibitor C1-INH product, higher marketing costs, due to increased competition for and with Pharming Group N. V. s RUCONEST a recombinant version market share.
of C1-INH, which has recently received European Medicines Agency EMA approval and will be launched in Europe by Swedish Orphan Shires strategy to become the leading specialty biopharmaceutical Biovitrum.
If approved in the US, FIRAZYR will compete with company has been developed to address industry-wide competitive BERINERT and with Dyax Corporations KALBITOR, a plasma pressures.
This strategy has resulted in a series of initiatives in the kallikrein inhibitor.
FIRAZYR will also compete indirectly with following areas: Viropharma, Inc. s CINRYZE, a plasma-derived CI-INH product approved in the US for prophylaxis of HAE attacks.
Markets Historically, Shires portfolio of approved products has been heavily HIV Market weighted towards the North American market.
The acquisition The HIV competitive landscape is becoming more crowded and in 2005 of Transkaryotic Therapies, Inc. TKT and the consequent complicated as treatment trends evolve.
The Groups 3TC lamivudine establishment of our HGT business, together with the acquisitions of EPIVIR products all licensed to GSK are part of the Nucleoside Jerini AG Jerini in 2008 which brought the HAE product FIRAZYR, Nucleotide Reverse Transcriptase Inhibitors NRTI market.
TRIZIVIR, EQUASYM in 2009 which facilitated Shires immediate access to the COMBIVIR and EPZICOM KIVEXA are part of the combined NRTI European ADHD market and Movetis NV Movetis in 2010 which market.
TRUVADA tenofovir emtricitabine, sold by Gilead, is the brought EU rights to RESOLOR and further developed our GI pipeline, market leader in combination NRTI.
In addition to the two NRTI HIV provided Shire with the platforms to increase its presence in Europe markets in which lamivudine is sold, there is competition from NRTIs, and the RoW, thereby working towards diversifying the risk associated PIs and entry inhibitors.
with reliance on one geographic market.
TRUVADA and ATRIPLA efavirenz emtricitabine tenofovir, a crossIn 2010 the SP and HGT businesses derived more than 17% and class fixed dose combination also sold by Gilead, both represent the 81%, respectively, of their product sales from outside of the US.
most direct competition to lamivudine.
Shire has made significant progress on a path to geographic diversification with additional development and commercialization Several generic drug companies have filed Abbreviated New Drug activities in 2010, including: Applications ANDAs seeking approval for EPIVIR, COMBIVIR, ZEFFIX and EPZICOM in the US and several tentative approvals of genericcontinued roll-out of MEZAVANT, FOSRENOL and FIRAZYR in lamivudine have been issued by the FDA.
Europe: and the acquisition of Movetis, which has added the approved product Strategy RESOLOR to the Groups European GI portfolio.
Shires strategic objectives are set using a balanced scorecard approach.
Strategic and operational objectives are set at the corporate Shires long-term mission is to increase the value of product sales level and cascaded to the segment SP HGT, therapeutic area and from outside of the US and outside of US, UK, Germany, France, functional levels so that these objectives are aligned with the corporate Italy, Spain and Canada.
Shire has ongoing late-stage development objectives.
The Group therefore takes a fully integrated approach to activities, which are expected to further supplement the diversification strategic management and uses key performance indicators KPIs of revenues in the future, and include the following: to measure the achievement of these objectives.
For 2010, Shires corporate KPIs included certain financial and non financial measures.
VYVANSE launches in Latin American countries and the registration program for approval in the EU: INTUNIV registration program for approval in the EU: See page 17 for details of Shires KPIs the continued roll-out of VPRIV in certain EU and Latin American countries: the continued roll-out of FIRAZYR in certain European and Latin American countries: the LIALDA MEZAVANT diverticulitis registration program: and the continued roll-out of FOSRENOL, EQUASYM and RESOLOR in EU and RoW countries.
Review of our business 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 13 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 13 R&D As expected, in 2009 Teva and Impax commenced commercial Over the last five years Shire has focused its R&D efforts on products shipments of their authorized generic versions of ADDERALL XR, in its core therapeutic areas and concentrated its resources on leading to declines in sales of branded ADDERALL XR in both 2009 obtaining regulatory approval for later-stage pipeline products within and 2010.
The FDA has not yet reached a decision on the Citizen these core therapeutic areas.
In addition to continued efforts in its Petition for ADDERALL XR which was filed in October 2005.
An FDA late-stage pipeline in core ADHD, GI and HGT therapeutic areas, decision which does not require generic follow-on products to require Shire has also progressed work on an earlier stage pipeline.
bio-equivalence or additional clinical testing could lead to additional generic competition for ADDERALL XR.
Evidence of the successful progression of the late-stage pipeline can be seen from the granting of approval and associated launches of the Shire is engaged in various legal proceedings with generic Groups products over the last six years.
Since January 2005, several manufacturers with respect to its VYVANSE, INTUNIV, FOSRENOL, products have received regulatory approval: in the US, ELAPRASE LIALDA and ADDERALL XR patents.
For more detail of current patent in 2006, LIALDA and VYVANSE in 2007, INTUNIV in 2009, and VPRIV litigation, see Note 20 Commitments and contingencies to the in 2010: in the EU, FOSRENOL in 2005, ELAPRASE and MEZAVANT consolidated financial statements.
in 2007, and VPRIV in 2010: in Canada, VYVANSE in 2010.
Products under development Shires strategy is focused on the development of product candidates The Group focuses its development resources on projects within that have a lower risk profile.
As Shire further expanded its earlier its core therapeutic areas of ADHD, GI, and HGT, as well as early phase pipeline, R&D costs in 2010 included expenditure on several development projects in additional therapeutic areas.
Total R&D pre-clinical to Phase 3 studies for products in development as well as expenditures of $661.5 million, $638.3 million and $494.3 million Phase 3 b and Phase 4 studies to support recently launched products were incurred in the years to December 31, 2010, 2009 and 2008 in the SP and HGT businesses, together with the development of new respectively.
projects in both the SP and HGT businesses.
The table below lists the Groups products in clinical development as Patents and market exclusivity of December 31, 2010 by disease areas indicating the most advanced The loss or expiration of patent protection or regulatory exclusivity with development status reached in key markets and the Groups territorial respect to any of the Groups major products could have a material rights in respect of each product.
adverse effect on the Groups revenues, financial condition and results of operations, as generic manufacturers may enter the market.
Generic manufacturers often do not need to complete extensive clinical studies when they seek registration of a copy product and accordingly, they are generally able to sell the Groups drugs at a much lower price.
SPECIALTY PHARMACEUTICALS Development status Products Disease area at December 31, 2010 The Groups territorial rights Treatments for ADHD INTUNIV extended release guanfacine For use in combination Registration in US Global with other ADHD treatments VYVANSE lisdexamfetamine dimesylate ADHD Phase 3 in EU Global INTUNIV ADHD Phase 3 in EU Global SPD 547 ADHD Phase 1 Global Treatments for GI diseases LIALDA mesalamine Maintenance of remission Registration in US Global excluding Italy 1 in ulcerative colitis and Canada and Latin America LIALDA mesalamine MEZAVANT mesalazine Diverticulitis Phase 3 globally Global excluding Italy 1 and Latin America RESOLOR prucalopride Chronic Constipation Males Phase 3 in EU Europe SPD 556 M0002 Ascites Phase 2 Global SPD 557 M0003 Refractory gastroesophageal Phase 2 EU and North America reflux disease GERD 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 14 14 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Financial review SPECIALTY PHARMACEUTICALS Development status Products Disease area at December 31, 2010 The Groups territorial rights Treatments for diseases in other therapeutic areas FOSRENOL lanthanum carbonate Chronic kidney disease Pre-registration Global CKD in pre-dialysis in the US patients XAGRID Essential thrombocythaemia Phase 3 in Japan Global 2 JUVISTA Improvement of Phase 2 US, Canada and Mexico scar appearance VYVANSE lisdexamfetamine dimesylate For Excessive Daytime Phase 2 Global Sleepiness EDS VYVANSE lisdexamfetamine dimesylate Adjunctive therapy in major Phase 2 Global depressive disorder MDD VYVANSE lisdexamfetamine dimesylate Other non ADHD Phase 2 Global indications in adults SPD 535 Arteriovenous grafts Phase 1 Global in hemodialysis patients HUMAN GENETIC THERAPIES Development status Products Disease area at December 31, 2010 The Groups territorial rights Treatments for Angiodema FIRAZYR icatibant Acute HAE Registration in the US Global Treatment for Duchenne muscular dystrophy DMD HGT-4510 DMD Phase 2a Global excluding 3 North America ERT 4 HGT-2310 Hunter Syndrome with Phase 1 2 Global central nervous system CNS symptoms, idursulfase-IT HGT-1410 Sanfilippo Syndrome Phase 1 2 Global  IIIA HGT-1110 Metachromatic Pre-clinical Global Leukodystrophy MLD 1 Mochida Pharmaceutical Co. Ltd has rights to develop and sell LIALDA in Japan under license with Shire.
2 Phase 3 studies being conducted by Renovo in Europe.
3 As a result of a license and collaboration agreement with Acceleron.
4 Genzyme has rights to manage marketing and distribution in Japan and certain other Asia Pacific countries under a license with Shire.
Review of our business 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 15 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 15 SPECIALTY PHARMACEUTICALS TREATMENTS FOR DISEASES IN OTHER THERAPEUTIC AREAS TREATMENTS FOR ADHD FOSRENOL for the treatment of pre-dialysis CKD Shire is continuing to explore the regulatory pathway required INTUNIV for use in combination with other ADHD treatments to secure a label extension in the US for FOSRENOL to treat On April 28, 2010 Shire submitted a supplemental New Drug hyperphosphatemia in pre-dialysis CKD.
application sNDA to support the efficacy and safety of INTUNIV when used in combination with other approved ADHD treatments.
XAGRID for the treatment of essential thrombocythaemia in Japan A Phase 3 clinical program has been initiated to assess the safety VYVANSE for ADHD in the EU and efficacy of XAGRID in adult essential thrombocythaemia patients VYVANSE for the treatment of ADHD in children aged 6 to 17 in the treated with cytoreductive therapy who have become intolerant to their EU is in Phase 3 development.
Shire anticipates submission of the filing current therapy or whose platelet counts have not been reduced to of a Marketing Authorization Approval MAA for VYVANSE in certain an acceptable level.
JUVISTA for the improvement of scar appearance INTUNIV for ADHD in the EU Renovo initiated its first pivotal European Phase 3 trial in scar revision in INTUNIV for the treatment of ADHD in children aged 6 to 17 in the EU the fourth quarter of 2008 to support the filing of a European regulatory is in Phase 3 development.
Shire anticipates submission of the filing dossier.
On February 11, 2011, Renovo announced its EU Phase 3 of an MAA for INTUNIV in certain countries in Europe in 2013. trial for JUVISTA in scar revision surgery did not meet its primary or secondary endpoints.
Shire is currently considering the trial data and SPD 547 Guanfacine Carrierwave, GCW whether to exercise its rights to terminate the license agreement.
for the treatment of ADHD SPD 547 is in early-stage development for the treatment of ADHD.
VYVANSE for the treatment of EDS The Phase 1 program is ongoing with results expected throughout On January 10, 2011 Shire announced results from a study of 2011.
GCW could potentially improve on the current guanfacine profile VYVANSE lisdexamfetamine dimesylate or SPD 489 assessing its to minimize known food, GI and sedation effects.
In this investigational, single dose, singlesite, randomized, placeboand active-controlled study, VYVANSE TREATMENTS FOR GI DISEASES was found to be statistically superior to placebo on both objective and subjective sleep measures.
Statistical superiority to the active LIALDA for the maintenance of remission in ulcerative colitis comparator 250 mg armodafinil was also found at higher VYVANSE in the US and Canada doses.
Shire plans to review potential development pathways with On June 14, 2010 Shire submitted a sNDA and supplemental New health authorities for VYVANSE as a possible EDS treatment option.
Drug Submission to the FDA and Health Canada, respectively, to seek approval for LIALDA for the maintenance of remission of ulcerative VYVANSE for the treatment of inadequate response in MDD colitis.
The product was indicated for the maintenance of remission A Phase 3 program to assess the efficacy and safety of VYVANSE in patients who have ulcerative colitis on approval in the EU.
as adjunctive therapy in patients with MDD is expected to be initiated in mid 2011, following health authority meetings to establish the LIALDA MEZAVANT for the treatment of diverticulitis development program parameters.
Phase 3 worldwide clinical trials investigating the use of LIALDA MEZAVANT to prevent recurrent attacks of diverticulitis VYVANSE for the treatment of other non ADHD indications in adults were initiated in 2007 and are ongoing.
Shire is conducting Phase 2 pilot clinical trials to assess the efficacy and safety of VYVANSE for the treatment of negative symptoms and RESOLOR for the treatment of chronic constipation in males cognitive impairment in schizophrenia and for the treatment of cognitive A Phase 3 European clinical trial to further assess the efficacy impairment in depression.
of RESOLOR for the treatment of chronic constipation in males was initiated in 2010 and is ongoing.
SPD 535 for the treatment of arteriovenous grafts in hemodialysis patients SPD 556 for the treatment of ascites SPD 535 is in development as a novel molecule with platelet lowering SPD 556 M0002 is a selective Vasopressin V2 receptor antagonist ability and without phosphodiesterase type III inhibition.
Phase 1 for the treatment of ascites.
This compound is ready for Phase 2 development was initiated in the third quarter of 2009 and is ongoing.
Data from Phase 1 clinical trials demonstrating positive proof-ofprinciple have been completed.
The initial proof-of-concept program SPD 557 for the treatment of refractory GERD will target prevention of thrombotic complications associated with SPD 557 M0003 is a selective 5-HT4 receptor agonist.
An exploratory arteriovenous grafts in hemodialysis patients.
Additional Phase 2 proofPhase 2 program to investigate the effect of the product on reflux of-concept clinical trials will also be initiated to assess opportunities episodes in patients currently treated with proton pump inhibitors in potential alternative indications.
was initiated in the fourth quarter 2010.
PROJECTS IN PRE-CLINICAL DEVELOPMENT A number of additional projects are underway in various stages of pre-clinical development for the SP area, including programs using Carrierwave technology, which are primarily focused in the area of pain management.
More data on these programs is expected throughout 2011.
8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 16 16 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Financial review HUMAN GENETIC THERAPIES Development projects discontinued during 2010 During 2010 the Group discontinued the following development project, TREATMENTS FOR ANGIOEDEMA which was included within Products under development in the Groups previous Annual Report: FIRAZYR for HAE in the US Prior to its acquisition by Shire, Jerini received a not approvable letter HGT-2610 for the treatment of Globoid cell leukodystrophy GLD for FIRAZYR for use in the US from the FDA in April 2008.
Shire agreed HGT-2610 was in early development as an ERT for the treatment with the FDA that an additional clinical study would be required before of GLD, an LSD.
This program has been suspended, due to the lower approval could be considered and that a complete response to the not observed incidence of infantile-onset GLD coupled with the rapidly approvable letter would be filed after completion of this study.
Shire has progressive nature of the disease, which challenged the feasibility now completed a Phase 3 study in patients with acute attacks of HAE, of clinical development.
known as the FAST-3 trial, and anticipates submitting a complete response to the FDA in early 2011. Business development As a result of the issues associated with the loss or expiry of patent TREATMENT FOR DMD protection or loss of data exclusivity, Shire seeks to focus its business development activity on the acquisition and in-licensing of products HGT-4510 for DMD and projects which have the benefit of long-term patent protection HGT-4510 also referred to as ACE-031 was added to the Shire HGT and or data exclusivity.
portfolio in 2010 through an exclusive license in markets outside of North America for the ActRIIB class of molecules being developed For example, through the acquisition of Movetis in 2010, Shire obtained by Acceleron.
The lead ActRIIB drug candidate, HGT-4510 is in recently launched RESOLOR, a promising GI pipeline and world-class development for the treatment of patients with DMD.
In 2010 Shire also acquired an exclusive license in markets trial is on hold and clinical safety is under review.
This product has outside of North America for the ActRIIB class of molecules being been granted orphan designation in the US and the EU.
The collaboration with Acceleron will initially Achieve revenue gr focus on further developing HGT-4510 also called ACE-031 for the Revenue growth fro ERT treatment of patients with DMD.
2010 HGT-2310 for the treatment of Hunter syndrome with CNS In 2009, Shire acquired the worldwide rights excluding the US, symptoms, idursulfase-IT intrathecal delivery Canada and Barbados to EQUASYM IR and XL from UCB and 2009 HGT-2310 is in development as an ERT delivered intrathecally for entered into a research collaboration with Santaris Pharma A S Hunter syndrome patients with CNS symptoms.
The Group initiated Santaris for the development of its Locked Nucleic Acid LNA a Phase 1 2 clinical trial in the first quarter of 2010.
2008 This product has been granted orphan designation in the US.
Organization and structure HGT-1410 for Sanfilippo A Syndrome  IIIA During 2010, to support the Groups mission to increase the proportion Revenues from net p HGT-1410 is in development as an ERT delivered intrathecally for of product sales generated outside of the US, Shire established an driven by strong grow the treatment of Sanfilippo A Syndrome  IIIA, international commercial hub in Switzerland.
ADDERALL XR Cor an lysosomal storage disorder LSD.
The product has been granted to $634 million, REP orphan drug designation in the US and in the EU.
The Group initiated 2010 outlook MEZAVANT up 24% a Phase 1 2 clinical trial in August 2010.
In August 2010 the Group announced that following its strong INTUNIV $166 million performance in the second quarter of 2010 it anticipated that Non 1 Products more than o HGT-1110for the treatment of MLD GAAP diluted earnings per ADS for the full year 2010 were trending sales following loss o Pre-clinical development of a formulation of HGT-1110, expressed from towards $4.00.
Shires human cell platform and suitable for direct delivery to the CNS, is ongoing.
The Group anticipates submission of an Investigational New In October 2010 the Group announced that following a stronger than 1 Achieve EBITDA g Drug application in late 2011.
This product has been granted orphan expected third quarter of 2010, it had increased its expectations for EBITDA $M drug designation in the US and the EU.
the full year 2010, and now expected Non GAAP diluted earnings per ADS of up to $4.20.
Actual Non GAAP diluted earnings per ADS for 2010 EARLY RESEARCH PRODUCTS the year ended December 31, 2010 was $4.23.
1 American Depositary Share A number of additional early stage research projects are underway 2009 Shire monitors its financial performance on a Non GAAP basis.
Non GAAP for the HGT business area.
financial measures are not prepared in accordance with US GAAP, and these Non GAAP measures exclude the effect of certain cash and non-cash items, 2008 both recurring and non-recurring, that Shires management believes are not related to the core performance of Shires business.
See page 123 to the consolidated financial statements for a reconciliation 1 EBITDA being Non G between US GAAP net income and diluted earnings per ADS and Non GAAP amortization is a Non net income and Non GAAP diluted earnings per ADS.
reconciled to their US Non GAAP EBITDA i revenues up 15% to leverage, which allow increased investmen in selling, general and our recent and future Review of our business 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 17 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 17 2010 PERFORMANCE OVERVIEW Our strategy principles Our purpose and mission are supported by a set of underlying strategy Our purpose principles: We enable people with life-altering conditions to lead better lives.
specialist focus: symptomatic diseases: unmet needs: niche markets: Our mission statement By 2015, Shire aspires to be the most valuable specialtyfocus on our best opportunities and be prepared to exit biopharmaceutical company in the world.
underperforming or low priority assets and businesses: strong bias towards out-sourcing non-differentiating capabilities: and To achieve these results Shire aims to: strong bias towards projects and technologies that have proof-ofdeliver leading financial performance within our peer group: concept in humans, are low-risk and allow for a quick development attain the number 1 or number 2 position in each of our chosen decision point.
therapeutic areas, as measured by global market share: KPIs grow sales in the mid-teens range year-on-year on average over Shire measures its performance against its mission statement and the course of 2009 through to 2015: and strategy using a Corporate Scorecard.
The objectives and KPIs in the have 50% of sales come from outside of the US and 25% of sales come Corporate Scorecard are reviewed and approved by the Companys from outside of the US, Germany, Italy, Spain, UK, France and Canada.
Remuneration Committee which also assesses how the Group has performed against those KPIs.
The 2010 Corporate Scorecard included the following financial and non financial KPIs: Financial KPIs 2 Achieve revenue growth from net product sales Achieve sales growth from ex-US markets Revenue growth from net product sales $BN Sales from outside the US % 2010 $3.1 2010 35% 2009 $2.7 2009 30% 2008 $2.8 2008 26% 2 Net product sales from geographic markets outside of the US.
Revenues from net product sales in 2010 were up 16% to $3.1 billion driven by strong growth from the Groups product sales excluding Product sales from ex-US markets grew by $300 million 37% ADDERALL XR Core Products including VYVANSE up 26% in 2010 and as a share of total product sales grew to $634 million, REPLAGAL up 81% to $351 million, LIALDA to 35% in 2010.
MEZAVANT up 24% to $293 million and recently launched INTUNIV $166 million and VPRIV $143 million.
Growth in Core Products more than offset the decline in ADDERALL XR product sales following loss of market exclusivity in April 2009.
1 3 Achieve EBITDA growth Achieve ROIC growth EBITDA $M Year-on year ROIC growth basis points 2010 $1,165 2010 v 2009 190 2009 $982 240 2009 v 2008 2008 $1,035 2008 v 2007 100 1 EBITDA being Non GAAP earnings before interest, tax, depreciation and 3 ROICNon GAAP Return on Invested Capital see page 122 for a denition.
amortization is a Non GAAP measure.
These Non GAAP measures are reconciled to their US GAAP equivalents on pages 123 to 125.
Non GAAP ROIC grew by 190 basis points in 2010 over 2009 primarily due to higher product sales up 16% and continued Non GAAP EBITDA increased during 2010 as a result of higher operating leverage leading to an increase in margins, together revenues up 15% to $3,471 million and continued operating with improvements in net asset efficiency.
leverage, which allowed the Group to absorb the effects of increased investment in our targeted R&D programs and increases in selling, general and administrative SG&A activities to support our recent and future growth.
8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 18 18 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Financial review Non financial KPIs Delivering tangible stakeholder value for: Non financial KPIs for 2010 included: Patients Achieve optimal global organization structure that supportsPhysicians Shires business model Payors Shire aims to develop a structure that best supports the Groups mission to increase the level of product sales generated outside Investors of the US.
Policymakers Shire has made good progress in achieving this objective.
In 2010 Shire 1 Represents growth over the 8 years from January 1, 2003 through December 31, established an international commercial hub in Nyon, Switzerland, and 2010. also a regional Latin American office in So Paulo, Brazil to support the 2 CAGRCompound Annual Growth Rate Groups rapid growth in that region.
3 EBITDANon GAAP earnings before interest, tax, depreciation and amortization.
Achieve a diversity of experiences and capabilities that reflect the expanding geographic diversity of Shires business Results of operations for the years to December 31, 2010 and 2009 Shire aims to ensure that its talent sourcing strategy supports Shires The Groups management analyzes product sales growth for certain geographic expansion and diversifies the Groups talent base, that it products sold in markets outside of the US on a constant exchange has development plans in place for its high potential employees and rate CER basis, so that product sales growth can be considered succession plans in place for its Leadership Team.
excluding movements in foreign exchange rates.
Product sales growth on a CER basis is a Non GAAP financial measure Non GAAP CER, Following the establishment of commercial hubs in Brazil and computed by comparing 2010 product sales restated using 2009 Switzerland, Shire recruited from both local and international talent average foreign exchange rates to 2009 actual product sales.
This pools for a range of positions, including senior positions, adding Non GAAP financial measure is used by Shires management, and is to the Groups diversity of employees.
considered to provide useful information to investors about the Groups results of operations, because it facilitates an evaluation of the Groups In 2010 Shires Leadership Team conducted a global talent review, year on year performance on a comparable basis.
Average key which included succession planning for its own membership, that exchange rates for the year to December 31, 2010 were $1.55:1.00 was presented to Shires Board of Directors.
Also during the year, and $1.33:1.00 2009: $1.57:1.00 and $1.39:1.00. development plans were completed for all high potential employees.
Financial highlights for the year to December 31, 2010 are as Achieve best-in-class ratings in target therapeutic areas follows: Shire aims to maintain a number one or number two global market Product sales were up 16% to $3,128 million 2009: $2,694 million.
share measured by US dollar sales for its ADHD and 5-ASA GI, Product sales excluding ADDERALL XR Core Product sales REPLAGAL, and VPRIV franchises.
In 2010, Shire maintained its grew strongly through 2010 up 34% to $2,767 million, more than number one position by market share in ADHD and was ranked offsetting the decline in ADDERALL XR product sales down 42% number two by market share in its 5-ASA franchise.
REPLAGAL to $361 million following loss of market exclusivity in April 2009. was the global market leader in 2010 and VPRIV, which was On a Non GAAP CER basis, Core Product sales were up 35%.
approved in both the US and EU in 2010, enabled Shire to help The 34% growth in Core Product sales to $2,767 million was driven meet significant patient demand following supply shortages of the by VYVANSE up 26% to $634 million, REPLAGAL up 81% to competitor treatment for Gaucher disease.
$351 million, LIALDA MEZAVANT up 24% to $293 million, and recently launched INTUNIV $166 million and VPRIV $143 million.
Our strategy is delivering Driving growth from a balanced product portfolio.
Total revenues were up 15% Non GAAP CER: up 16% to $3,471 million 2009: $3,008 million due to the growth in product Financial impact 20032010 sales and higher royalties up 12% to $328 million.
1 2 Growth CAGR Operating income increased by $174 million, or 28%, to $794 million Total revenues 235% 16% 2009: $620 million, due to higher revenues and continued operating 3 EBITDA 198% 15% leverage, allowing us to absorb the effects of increased investment in our targeted R&D programs and an increase in SG&A activities to support our recent and future growth.
Net income attributable to Shire increased by $96 million to $588 million 2009: $492 million and diluted earnings per Ordinary Share increased by 17% to 105.3 2009: 89.7. Review of our business 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 19 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 19 Total revenues The following table provides an analysis of the Groups total revenues by source: 2010 2009 Change Year to December 31, $M $M % Product sales 3,128.2 2,693.7 16% Royalties 328.1 292.5 12% Other revenues 14.8 21.5 31% Total 3,471.1 3,007.7 15% Product sales Year to Year to December 31, December 31, Product sales Non GAAP CER US prescription Exit market 1 1 2010 2009 growth growth growth share $M $M % % % % SPECIALTY PHARMACEUTICALS ADHD VYVANSE 634.2 504.7 26 26 28 15 ADDERALL XR 360.8 626.5 42 43 32 7 4 4 4 INTUNIV 165.9 5.4 n a n a n a 3 5 DAYTRANA 49.4 71.0 30 30 n a n a 2 EQUASYM 22.0 22.8 4 1 n a n a GI LIALDA MEZAVANT 293.4 235.9 24 24 18 20 PENTASA 235.9 214.8 10 10 5 15 3 3 RESOLOR 0.3 n a n a n a n a General products FOSRENOL 182.1 184.4 1 1 16 6 2 XAGRID 87.3 84.8 3 7 n a n a CARBATROL 82.3 82.4 1 1 7 57 2 REMINYL REMINYL XL 42.9 42.4 1 2 n a n a 2 CALCICHEW 38.9 43.7 11 10 n a n a Other product sales 23.8 19.4 23 17 n a n a 2,219.2 2,138.2 4 HUMAN GENETIC THERAPIES 2 2 ELAPRASE 403.6 353.1 14 16 n a n a 3 3 REPLAGAL 351.3 193.8 81 87 n a n a 4 4 2 VPRIV 143.0 2.5 n a n a n a n a 3 3 FIRAZYR 11.1 6.1 82 91 n a n a 909.0 555.5 64 Total product sales 3,128.2 2,693.7 16 1 Data provided by IMS Health National Prescription Audit IMS NPA.
Exit market share represents the average monthly US market share in the month ended December 31, 2010.
2 IMS NPA data not available.
3 Not sold in the US in the year to December 31, 2010.
4 INTUNIV was launched in the US in the fourth quarter of 2009.
In 2009 VPRIV generated sales from early access programs prior to obtaining US and EU approval in 2010.
5 The Group divested DAYTRANA to Noven effective October 1, 2010.
8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 20 20 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Financial review SPECIALTY PHARMACEUTICALS Should CMS require Shire to apply an alternative interpretation of the Medicaid rebate legislation for the period prior to October 1, 2010, Shire VYVANSEADHD could seek to limit any additional payment for 2009 rebates to a level The increase in VYVANSE product sales was driven by both an approximating the full, un-rebated cost to the States of ADDERALL XR, increase in VYVANSE market share and US ADHD market growth or $130 million above the recorded liability.
Further, Shire believes it has 12% as well as the effect of price increases taken since the fourth a strong legal basis supporting its interpretation of the Medicaid rebate quarter of 2009.
These factors offset the effect of higher sales legislation, and that there would be a strong basis to initiate litigation deductions in 2010 due to the impact of increased Medicaid rebates to recover any amount paid in excess of the recorded liability.
The result principally as a result of US Healthcare Reforms.
of any such litigation cannot be predicted and could result in additional rebate liability above Shires current best estimate.
Information regarding litigation proceedings with respect to VYVANSE can be found in Note 20 Commitments and contingencies to the Litigation proceedings regarding ADDERALL XR are ongoing.
information about this litigation can be found in Note 20 Commitments and contingencies to the consolidated financial statements.
ADDERALL XRADHD ADDERALL XR product sales decreased due to lower US prescription INTUNIVADHD demand following the launch of authorized generic versions in 2009, US prescription demand for INTUNIV continued to increase throughout which more than offset US ADHD market growth and higher sales 2010.
INTUNIV was launched in the US in November 2009, and deductions in 2010 65% of branded gross sales in 2010 compared product sales in 2010 included both shipments made in 2010 to 47% in 2009.
These factors more than offset the effects of stocking and the recognition into revenue of launch stocks which had been in 2010 compared to fide-stocking in 2009. deferred in 2009 in accordance with Shires accounting policies.
There are potentially different interpretations as to how shipments Litigation proceedings relating to the Groups INTUNIV patents are of authorized generic ADDERALL XR to Teva and Impax should be in progress.
For further information see Note 20 Commitments and included in the Medicaid rebate calculation pursuant to Medicaid rebate contingencies to the consolidated financial statements.
legislation, including the Deficit Reduction Act of 2005 the Medicaid rebate legislation.
As a result, more than one unit rebate amount LIALDA MEZAVANTUlcerative colitis URA is calculable for the purposes of determining the Groups Product sales for LIALDA MEZAVANT continued to grow in 2010, Medicaid rebate liability to the States after authorized generic launch.
driven by an increase in US market share and price increases taken In the years to December 31, 2010 and 2009, the Group has recorded since the fourth quarter of 2009.
These factors were partially offset its accrual for Medicaid rebates based on its best estimate of the by higher sales deductions compared to the same period in 2009 rebate payable.
This best estimate is consistent with i the Groups due in part to US Healthcare Reforms.
interpretation of the Medicaid rebate legislation, as amended in 2010 by the relevant provisions of the 2010 Affordable Care Act, ii the Litigation proceedings regarding LIALDA MEZAVANT are ongoing.
Further Groups repeated and consistent submission of price reporting to the information about this litigation can be found in Note 20 Commitments Center for Medicare and Medicaid Services, CMS using the Groups and contingencies to the consolidated financial statements.
interpretation of the Medicaid rebate legislation, iii CMS calculating the URA based on that interpretation, iv States submitting Medicaid PENTASAUlcerative colitis rebate invoices using this URA, and v Shire paying these invoices.
Product sales of PENTASA continued to grow despite lower US prescription demand due to the impact of price increases taken Shire believes that its interpretation of the Medicaid rebate legislation during 2010. is reasonable and correct.
In addition, the 2010 Affordable Care Act contained a provision, effective as of October 1, 2010, that provided RESOLORChronic constipation further clarity, in a manner consistent with the Groups interpretation, RESOLOR has generated revenues of $0.3 million since acquisition as to how shipments of authorized generics should be included in in October 2010 and sales are expected to be higher in 2011 as the Medicaid rebate calculations from October 1, 2010 forward.
CMS product is launched in additional countries and captures a full year has explicitly referred manufacturers with authorized generics to this of revenue in existing markets.
new provision in making their branded rebate calculations, further supporting the Groups interpretation.
 Product sales of FOSRENOL outside the US increased by 6% primarily However, CMS could disagree with the Groups interpretation for because of higher prescription demand partially offset by mandatory determining Medicaid rebates payable for the period prior to October 1, price reductions that were imposed in 2010.
Product sales of 2010, and require Shire to apply an alternative interpretation of the FOSRENOL in the US decreased by 7% due to lower US prescription Medicaid rebate legislation and pay up to $210 million above the demand and higher sales deductions compared to 2009, which more recorded liability.
For rebates in respect of 2009 prescriptions 2009 than offset the effect of price increases taken since the fourth quarter rebates this would represent a URA substantially in excess of the of 2009. unit sales price of ADDERALL XR and accordingly in excess of the approximate amount of the full cost to the States of reimbursement Litigation proceedings regarding Shires FOSRENOL patents are for Medicaid prescriptions of ADDERALL XR.
For rebates in respect ongoing.
Further information about this litigation can be found in of 2010 prescriptions, as a result of provisions in the 2010 Affordable Note 20 Commitments and contingencies to the consolidated Care Act, the URA would be limited to an amount approximating financial statements.
the unit sales price of ADDERALL XR.
Review of our business 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 21 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 21 HUMAN GENETIC THERAPIES Litigation proceedings regarding REPLAGAL are ongoing.
Further information about this litigation can be found in Note 20 Commitments ELAPRASEHunter syndrome and contingencies to the consolidated financial statements.
The growth in sales of ELAPRASE was driven by new patients commencing therapy across North America, Latin America and VPRIVGaucher disease Europe, Middle East and Asia.
On a Non GAAP CER basis sales Following the grant of a marketing authorization from the European grew by 16%.
Commission on August 26, 2010, VPRIV is now being reimbursed on an approved basis in several countries in the EU as well as REPLAGALFabry disease in the US.
VPRIV was approved by the FDA on February 26, 2010.
The 81% growth 87% on a Non GAAP CER basis in REPLAGAL Reimbursement on a pre-approval basis continues in other EU product sales was driven by a significant increase in demand in 2010 countries.
in all countries where REPLAGAL is sold as new patients commenced therapy and existing patients switched to REPLAGAL from a FIRAZYRHAE competitor product.
This was attributable in part to supply shortages Product sales grew in line with increased volumes across markets of that competitor product.
FIRAZYR is the first new product for HAE in Europe in 30 years and has orphan exclusivity for acute attacks of HAE in adults in the EU until 2018.
Royalties Royalty revenue increased by 12% to $328.1 million for the year to December 31, 2010 2009: $292.5 million.
The following table provides an analysis of Shires royalty income: 2010 2009 Change Year to December 31, $M $M % 3TC and ZEFFIX 154.0 164.0 6% ADDERALL XR 100.3 68.0 48% Other 73.8 60.5 22% Total 328.1 292.5 12% The increase in royalty revenue in 2010 was primarily due to higher royalties received on sales of authorized generic versions of ADDERALL XR ADDERALL XR royalties have been received from Impax since October 2009, and were received from Teva, at a lower rate, between April and September 2009.
Royalties received for 3TC and Zeffix from GSK were lower in 2010 compared to 2009 as 3TC based treatments continue to be adversely impacted by increased competition from other products.
Cost of product sales R&D Cost of product sales increased to $463.4 million for the year to R&D expenditure for the year to December 31, 2010 increased to December 31, 2010 15% of product sales, up from $388.0 million $661.5 million 21% of product sales, compared to $638.3 million in the corresponding period in 2009 14% of product sales.
Cost in the corresponding period in 2009 24% of product sales.
R&D of product sales as a percentage of product sales increased by expenditure in the year to December 31, 2010 included the up-front one percentage point compared to 2009 as lower gross margins payment of $45.0 million 1% of product sales on entering the on ADDERALL XR in 2010 and higher costs incurred in 2010 on the collaboration with Acceleron for development of the ActRIIB class transfer of manufacturing from the Groups Owings Mills facility to of molecules.
R&D in the year to December 31, 2009 included a third-party offset the positive effect on gross margins of recently $36.9 million 1% of product sales related to the payment to amend launched, higher margin products and higher gross margins from an INTUNIV in-license agreement, $62.9 million 2% of product existing Core Products.
sales following the agreement with Duramed Pharmaceuticals, Inc. Duramed to terminate development of the Womens Health For the year to December 31, 2010 cost of product sales included products, and the up-front payment to Santaris of $6.5 million for depreciation of $38.1 million 2009: $21.8 million.
Depreciation technology access and R&D funding.
charged in 2010 is higher than 2009 due to accelerated depreciation of $25.7 million 2009: $12.0 million following a change in the estimate Excluding these termination, license and up-front payments, of the useful lives of the property, plant and equipment at Shires R&D increased by $84.5 million in the year to December 31, 2010 Owings Mills facility as a result of the anticipated closure of the facility compared to the same period in 2009 as the Group has continued in 2011. to increase investment in a number of targeted R&D programs, including VYVANSE international and investigative uses of VYVANSE for new indications, Guanfacine Carrierwave, R&D programs acquired with Movetis and other early stage development programs.
For the year to December 31, 2010 R&D included depreciation of $19.0 million 2009: $15.5 million.
8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 22 22 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Financial review SG&A Taxation SG&A expenses increased to $1,526.3 million 49% of product sales The effective rate of tax in 2010 was 24% 2009: 22%.
for the year to December 31, 2010 from $1,342.6 million 50% of product sales in the corresponding period in 2009.
SG&A increased The effective rate of tax in 2010 benefited from increased profits in in 2010 compared to the same period in 2009 due to costs incurred lower tax territories, including Switzerland following the implementation to support the launches of INTUNIV and VPRIV, growth in new markets of an international commercial hub there in 2010, and an increase in and the inclusion of Movetis operating costs from the fourth quarter US tax incentives notably the domestic production deduction partially of 2010 following completion of the acquisition.
For the year to offset by up-front payments to Acceleron which were deductible at tax December 31, 2010 SG&A also included depreciation of $62.1 million rates lower than the Groups effective tax rate.
2009: $67.7 million, intangible asset amortization of $133.5 million 2009: $136.9 million and intangible asset impairment charges The effective rate of tax in 2009 benefited from the decrease in valuation of $42.7 million 2009: $nil to write-down the DAYTRANA intangible allowances relating to state tax credits and loss carry-forwards following asset to its fair value less costs to sell prior to divestment to Noven.
Massachusetts state tax changes, and the favorable rate effect of the termination of the Womens Health development agreement with Gain on sale of product rights Duramed and the amendment to the INTUNIV in-license, which were For the year to December 31, 2010 the Group recorded gains both tax effected at rates higher than the Groups effective rate.
on sale of product rights of $16.5 million 2009: $6.3 million of which $10.4 million 2009: $nil resulted from the re-measurement of Results of operations for the years to December 31, 2009 contingent consideration receivable on divestment of DAYTRANA and 2008 to its fair value, and $6.1 million 2009: $6.3 million from the disposal Key financial highlights for the year to December 31, 2009 were of other non-core products.
as follows: Core Product sales increased by 25% to $2,067.2 million Re-organization costs 2008: $1,652.5 million following continued strong growth from For the year to December 31, 2010 Shire recorded re-organization VYVANSE, LIALDA MEZAVANT, ELAPRASE and REPLAGAL: costs of $34.3 million 2009: $12.7 million of which $13.0 million 2009: $12.7 million related to the transfer of manufacturing from itsProduct sales including ADDERALL XR decreased by 2% to Owings Mills facility to a third-party and $21.3 million 2009: $nil related $2,693.7 million 2008: $2,754.2 million due to the expected decline to the establishment of an international commercial hub in Switzerland.
in ADDERALL XR product sales following the launch of authorized generic versions by Teva and Impax, with the strong performance Integration and acquisition costs from Shires other products offsetting the decrease: For the year to December 31, 2010 the Group recorded integration Total revenues decreased marginally to $3,007.7 million 2008: and acquisition costs of $8.0 million 2009: $10.6 million, which $3,022.2 million as the increase in product sales excluding in 2010 principally related to the acquisition of Movetis, and in 2009 ADDERALL XR and royalty income received on Teva and Impaxs to the integration of Jerini.
sales of authorized generic ADDERALL XR offset the decline in ADDERALL XR product sales: Interest expense For the year to December 31, 2010 the Group incurred interest Operating income in 2009 increased by 51% to $620.2 million expense of $35.1 million 2009: $39.8 million.
Interest expense 2008: $412.0 million : and principally relates to the coupon and amortization of issue costs Net income attributable to Shire plc increased by $335.6 million on Shires $1,100 million 2.75% convertible bonds due 2014. to $491.6 million 2008: $156.0 million and diluted earnings per Ordinary Share increased to 89.7 in 2009 2008: 28.6.
Other income expense, net For the year to December 31, 2010 the Group recognized other income, net of $7.9 million 2009: $60.7 million, primarily due to the recognition of a gain of $11.1 million 2009: $55.2 million relating to the disposal of its investment in Virochem Pharma Inc. Virochem in March 2009.
At the time of disposal an element of the consideration was held in escrow for twelve months pending any warranty claims.
The consideration was released from escrow in March 2010, resulting in the remaining gain being recognized in the year to December 31, 2010.
Other income expense, net also includes a loss of $3.6 million in the year to December 31, 2010 relating to the extinguishment of building finance obligations at Lexington Technology Park LTP, and in 2009 includes a gain of $5.7 million following the substantial modification of a property lease.
Review of our business 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 23 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 23 Total revenues The following table provides an analysis of the Groups total revenues by source: 2009 2008 Change Year to December 31, $M $M % Product sales 2,693.7 2,754.2 2 Royalties 292.5 245.5 19 Other revenues 21.5 22.5 4 Total 3,007.7 3,022.2 Product sales Year to Year to December 31, December 31, Product sales Non GAAP CER US prescription Exit market 1 1 2009 2008 growth growth growth share $M $M % % % % SPECIALTY PHARMACEUTICALS ADHD VYVANSE 504.7 318.9 58 58 65 13 ADDERALL XR 626.5 1,101.7 43 43 42 8 DAYTRANA 71.0 78.7 10 10 13 1 2 EQUASYM 22.8 n a n a n a n a INTUNIV 5.4 n a n a n a 1 GI PENTASA 214.8 185.5 16 16 2 16 LIALDA MEZAVANT 235.9 140.4 68 69 43 18 General products FOSRENOL 184.4 155.4 19 23 2 8 3 CALCICHEW 43.7 52.8 17 3 n a n a CARBATROL 82.4 75.9 9 9 4 55 3 REMINYL REMINYL XL 42.4 34.4 23 42 n a n a 2 XAGRID 84.8 78.7 8 16 n a n a 3 Other product sales 19.4 50.1 61 59 n a n a 2,138.2 2,272.5 6 HUMAN GENETIC THERAPIES 3 ELAPRASE 353.1 305.1 16 20 n a n a 2 REPLAGAL 193.8 176.1 10 16 n a n a 2 FIRAZYR 6.1 0.5 n a n a n a n a 4 2 VPRIV 2.5 n a n a n a n a 555.5 481.7 15 Total product sales 2,693.7 2,754.2 2 1 US prescription growth and market share data provided by IMS NPA.
Exit market share represents the US market share in the last week of December 2009.
2 Not sold in the US or awaiting approval in the US.
3 IMS NPA data not available.
Sales achieved under early access programs.
The Groups management analyses product sales growth for certain products sold in markets outside of the US on a CER basis, so that product sales growth can be considered excluding movements in foreign exchange rates.
Product sales growth on a CER basis is a non GAAP financial measure, computed by comparing 2009 product sales restated using 2008 average foreign exchange rates to 2008 actual product sales.
8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 24 24 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Financial review SPECIALTY PHARMACEUTICALS LIALDA MEZAVANTUlcerative colitis Strong product sales of LIALDA MEZAVANT continued in the year to VYVANSEADHD December 31, 2009 driven by an increase in market share over 2008, The increase in VYVANSE product sales was driven by higher growth in the US oral mesalamine market and price increases taken US prescription demand in 2009 compared to 2008, 9% growth during 2009. in the US ADHD market and price increases.
Product sales growth was lower than prescription growth due to lower stocking in 2009 Litigation proceedings regarding LIALDA MEZAVANT are ongoing.
Further information about this litigation can be found in Note 20 Commitments and contingencies to the consolidated financial Information regarding litigation proceedings with respect to VYVANSE statements.
can be found in Note 20 Commitments and contingencies to the consolidated financial statements.
 Product sales increased as FOSRENOL entered new countries and ADDERALL XRADHD grew in existing markets outside the US.
In the US, FOSRENOL sales The launch by Teva and Impax of their authorized generic versions grew despite lower prescriptions due to a price increase in 2009. of ADDERALL XR led to the expected decline in 2009 of branded ADDERALL XR prescription demand, and resulted in higher US sales Litigation proceedings regarding Shires FOSRENOL patents are deductions in 2009 compared to 2008.
These factors more than offset ongoing.
Further information about this litigation can be found in the positive impacts of price increases taken since the fourth quarter Note 20 Commitments and contingencies to the consolidated of 2008, and the inclusion in product sales of shipments of authorized financial statements.
generic ADDERALL XR to Teva and Impax in 2009.
HUMAN GENETIC THERAPIES Sales deductions represented 47% of branded ADDERALL XR gross sales in the year to December 31, 2009 compared to 25% in the same ELAPRASEHunter syndrome period in 2008, following higher Medicaid and Managed Care rebates The growth in sales of ELAPRASE was driven by increased volumes subsequent to the authorized generic launches.
across all regions where ELAPRASE is sold.
On a Non GAAP CER basis sales grew by 20% 66% of ELAPRASE sales are made outside Litigation proceedings regarding ADDERALL XR are ongoing.
REPLAGALFabry disease The growth in REPLAGAL product sales in 2009 over 2008 was INTUNIVADHD driven by a significant increase in demand in the fourth quarter of 2009 INTUNIV was launched in the US in November 2009.
In line with due to an acceleration of patients switching to REPLAGAL in the EU, Shires revenue recognition policy for launch shipments, initial stocking attributable in part to supply shortages affecting a competitor product.
shipments have been deferred and are being recognized into revenue Sales increased 16% on a Non GAAP CER basis REPLAGAL is sold in line with end-user prescription demand.
At December 31, 2009 primarily in Euros and Pounds sterling.
deferred revenues on the balance sheet represented gross sales of $38.8 million.
Litigation proceedings regarding REPLAGAL are ongoing.
Further information about this litigation can be found in Note 20 Commitments Litigation proceedings relating to the Groups INTUNIV patents are and contingencies to the consolidated financial statements.
For further information see Note 20 Commitments and contingencies to the consolidated financial statements.
PENTASAUlcerative colitis Product sales of PENTASA continued to grow despite a decrease in US prescription demand in 2009 compared to 2008 due to the impact of price increases taken during 2009. Review of our business 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 25 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 25 Royalties Royalty revenue increased by 19% to $292.5 million for the year to December 31, 2009 2008: $245.5 million.
The following table provides an analysis of Shires royalty income: Non GAAP 2009 2008 Change CER Year to December 31, $M $M % % 3TC and ZEFFIX 164.0 180.5 9 6 ADDERALL XR 68.0 n a n a Others 60.5 65.0 7 3 Total 292.5 245.5 19 22 3TC HIV infection and Acquired Immunodeficiency Syndrome R&D AIDS and ZEFFIX Chronic hepatitis B infection R&D expenditure increased by 29% to $638.3 million in the year Shire receives royalties from GSK on worldwide 3TC and ZEFFIX sales, to December 31, 2009 24% of product sales, up from $494.3 million which have decreased mainly due to competition from other HIV and in the corresponding period in 2008 18% of product sales.
the year to December 31, 2009 included a charge of $36.9 million 1% of product sales relating to the amendment of an INTUNIV inADDERALL XRADHD license agreement and costs of $62.9 million 2% of product sales Royalties were received on Tevas sales of an authorized generic following the agreement with Duramed to terminate the Womens version of ADDERALL XR between April 2009 and September 2009, Health development agreement.
R&D in the year to December 31, and on Impaxs sales of an authorized generic version of ADDERALL 2008 included costs of $6.5 million for DYNEPO exit costs.
Excluding XR from October 2009. these items, R&D increased in the year to December 31, 2009 compared to the same period in 2008 due to continued investment Other in R&D programs, including the acceleration of investment in VPRIV Other royalties are received primarily on worldwide excluding UK and REPLAGAL in the US, and the inclusion within R&D of an and Republic of Ireland sales of REMINYL and REMINYL XL known up-front payment of $6.5 million to Santaris for technology access as RAZADYNE and RAZADYNE ER in the US.
Royalties on sales and R&D funding.
of these products decreased in the year to December 31, 2009 to $47.7 million 2008: $63.5 million due to generic competition For the year to December 31, 2009 R&D included depreciation in the US from August 2008. of $15.5 million 2008: $12.5 million.
Cost of product sales SG&A Cost of product sales decreased to $388.0 million for the year to SG&A expenses decreased to $1,342.6 million 50% of product sales December 31, 2009 14% of product sales, down from $408.0 million for the year to December 31, 2009 from $1,455.2 million 53% of in the corresponding period in 2008 2008: 15% of product sales.
product sales in the corresponding period in 2008.
The decrease was Cost of product sales in the year to December 31, 2008 included due to the Groups continued focus on cost management, and lower charges relating to DYNEPO exit costs of $48.8 million 2% of product intangible asset impairment charges in the year to December 31, 2009 sales.
Excluding this item, cost of product sales as a percentage of compared to the same period in 2008.
SG&A in the year to December product sales in 2009 increased by 1% to 14% compared to 2008.
31, 2009 included intangible asset amortization of $136.9 million 2008: This increase primarily resulted from changes in product mix following $126.2 million, the increase resulting from a full year amortization of the FIRAZYR intangible asset.
Intangible asset impairment charges in the the launch by Teva and Impax of their authorized generic versions of ADDERALL XR in 2009.
Higher sales deductions on Shires sales year to December 31, 2009 were $nil 2008: $97.1 million.
Impairment charges in 2008 included $94.6 million related to DYNEPO which the of branded ADDERALL XR, together with lower margin sales of the authorized generic version of ADDERALL XR to Teva and Impax both Group ceased to commercialize.
Depreciation included in SG&A was $67.7 million in 2009 2008: $48.5 million.
Gain on sale of product rights For the year to December 31, 2009 cost of product sales included depreciation of $21.8 million 2008: $16.2 million.
Depreciation For the year to December 31, 2009 Shire recorded gains of $6.3 million 2008: $20.7 million arising from the sale of non-core products to charged in 2009 is higher than 2008 due to accelerated depreciation of $12.0 million in 2009 following a change in the estimate of the Almirall in 2007.
These gains had been deferred since 2007 pending obtaining the relevant consents to transfer certain assets.
useful lives of the property, plant and equipment at Shires Owings Mills facility as a result of the anticipated closure of the facility in 2011.
8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 26 26 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Financial review In-process R&D IPR&D charge Other income expense, net During the year to December 31, 2009 the Group recorded an IPR&D For the year to December 31, 2009 the Group recognized Other charge of $1.6 million 2008: $128.1 million, in respect of FIRAZYR income, net of $60.7 million.
Other income in 2009 includes a gain in markets outside of the EU which have not been approved by the of $55.2 million on disposal of the Groups investment in Virochem to relevant regulatory authorities.
Also included in IPR&D in 2008 was Vertex Pharmaceuticals Inc. Vertex in a cash and stock transaction.
a charge of $135.0 million relating to the acquisition of METAZYM Shire received total consideration of $19.2 million in cash and two from Zymenex.
million Vertex shares valued at $50.8 million at the date these shares were acquired.
Other income, net in 2009 also includes a gain The IPR&D charge in respect of FIRAZYR relates to the US of $5.7 million on the substantial modification of a property lease.
$64.9 million and the RoW $64.8 million markets.
In the US, Jerini received a not approvable letter with respect to FIRAZYR For the year ended December 31, 2008, the Group recognized Other from the FDA in April 2008 prior to the acquisition of Jerini by Shire, expenses, net of $32.9 million.
Other expenses, net includes otherand Shire has since agreed to conduct an additional clinical study in than-temporary impairment charges of $58.0 million.
Impairment certain RoW territories where FIRAZYR has not been approved by charges in 2008 include $44.3 million relating to the Groups availablethe regulatory authorities.
for-sale investment in Renovo Group plc.
Offsetting this in 2008 is a gain of $9.4 million from the disposal of the Groups available-for-sale METAZYM HGT-1111 completed a Phase 1b clinical trial in 12 MLD investment in Questcor Pharmaceutical Inc. Questcor for cash patients in Europe and an extension to this study is ongoing.
on additional long-term clinical data from the ongoing Phase 1b study in MLD, in the first quarter of 2010 Shire decided to suspend further Taxation development of an intravenous formulation of HGT-1111.
In the year to December 31, 2009 the effective tax rate was 22% 2008: 37%.
Excluding the impact of IPR&D charges of $263.1 million Re-organization costs in 2008, which are either not tax deductible or for which no tax benefit For the year to December 31, 2009 Shire recorded re-organization is currently recognized, the effective tax rate in 2008 was 19%.
costs of $12.7 million 2008: $nil relating to the transfer of manufacturing from its Owings Mills facility.
The effective rate of tax in 2009 was higher than 2008 excluding the impact of IPR&D charges due to increased profits in higher tax Integration and acquisition costs territories, and the recognition of valuation allowances against EU For the year to December 31, 2009 Shire recorded integration and and US deferred tax assets.
These factors more than offset reductions acquisition costs of $10.6 million 2008: $10.3 million primarily relating to the effective rate of tax in 2009 due to: the decrease in valuation to the integration of Jerini.
allowances relating to state tax credits and loss carry-forwards following Massachusetts State tax changes in 2009: the benefit of Interest income the effect of the change in the effective state tax rate on the net state For the year to December 31, 2009 Shire received interest income deferred tax balance: and higher R&D tax credits in the US, principally of $1.9 million 2008: $25.5 million, primarily earned on cash and cash the acceleration of the VPRIV program.
Interest income for the year to December 31, 2009 was lower than the same period in 2008 due to significantly lower average Discontinued operations interest rates in 2009 compared to 2008 and lower average cash and The loss from discontinued operations for the year to December 31, cash equivalent balances.
The loss in 2009 related to net losses on discontinued Jerini businesses which were either Interest expense divested or closed during the second quarter of 2009, the loss For the year to December 31, 2009 the Group incurred interest on disposal of Jerini Peptide Technologies GmbH JPT business and expense of $39.8 million 2008: $139.0 million.
Interest expense in the write-off of assets previously classified as held-for-sale.
The loss 2009 primarily related to interest expense on the Groups convertible in 2008 related to certain businesses acquired through the Jerini bond.
Interest expense in 2008 was higher than 2009 due to interest acquisition, including a charge of $12.9 million arising on the reexpense of $87.3 million recorded in respect of the TKT appraisal measurement of assets held-for-sale to their fair value less cost to sell.
rights litigation, of which $73.0 million was additional interest arising from the settlement of the litigation in November 2008. Review of our business 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 27 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 27 Financial condition at December 31, 2010 and 2009 Liquidity and capital resources Cash and cash equivalents General Cash and cash equivalents have increased by $51.7 million The Groups funding requirements depend on a number of factors, to $550.6 million at December 31, 2010 December 31, 2009: including the timing and extent of its development programs: corporate, $498.9 million.
In the year to December 31, 2010 cash provided by business and product acquisitions: the level of resources required for operating activities was $954.9 million.
The strong operating cashflow the expansion of manufacturing and marketing capabilities as the in 2010 has funded significant investment in the business, including product base expands: increases in accounts receivable and inventory the acquisition of Movetis, LTP and other capital expenditures as well which may arise with any increase in product sales: competitive and as enabling a reduction of net debt.
technological developments: the timing and cost of obtaining required regulatory approvals for new products: the timing and quantum of Accounts receivable, net milestone payments on collaborative projects: the timing and quantum Accounts receivable, net have increased by $95.0 million of tax and dividend payments: the timing and quantum of purchases to $692.5 million at December 31, 2010 December 31, 2009: by the Employee Share Ownership Trust ESOT of Shire shares in $597.5 million, principally due to higher gross revenues in 2010 the market to satisfy option exercises: the timing and quantum of any compared to 2009.
At December 31, 2010 receivables represented amount that could be paid by the Group if CMS were to employ 50 days sales, a reduction of one day compared to 2009 December an alternative interpretation of the URA in respect of ADDERALL XR 31, 2009: 51 days.
Medicaid rebates: and the amount of cash generated from sales of Shires products and royalty receipts.
Inventories Inventories have increased by $70.3 million to $260.0 million at An important part of Shires business strategy is to protect its products December 31, 2010 December 31, 2009: $189.7 million, primarily and technologies through the use of patents, proprietary technologies due to an increase in the production of the Groups HGT products.
and trademarks, to the extent available.
The Group intends to defend its intellectual property and as a result may need cash for funding the Property, plant and equipment, net cost of litigation.
Property, plant and equipment, net increased by $176.6 million to $853.4 million at December 31, 2010 December 31, 2009: The Group finances its activities through cash generated from operating $676.8 million, principally due to the acquisition of and construction activities: credit facilities: private and public offerings of equity and debt at LTP.
securities: and the proceeds of asset or investment disposals.
Other intangible assets, net Shires balance sheet includes $550.6 million of cash and cash Other intangible assets, net have increased by $188.2 million equivalents at December 31, 2010.
Substantially all of Shires debt to $1,978.9 million at December 31, 2010 December 31, 2009: relates to its $1,100 million 2.75% convertible bond which matures in $1,790.7 million as a result of intangible assets recognized through 2014, although these bonds include a put option which could require the Movetis business combination, partially offset by amortization repayment of the bonds in 2012.
In addition, in November 2010 Shire and impairment charges, the disposal of the DAYTRANA intangible entered into a new committed multicurrency revolving and swingline asset and translational foreign exchange losses on non-US dollar facilities agreement of $1,200 million, which is currently undrawn, and denominated intangible assets.
The Groups existing committed revolving credit facility was cancelled.
Accounts payable and accrued expenses Accounts payable and accrued expenses have increased Shire 2.75% convertible bonds due 2014 by $310.2 million to $1,239.3 million December 31, 2009: On May 9, 2007 Shire issued $1,100 million in principal amount $929.1 million, primarily due to increases in accrued Medicaid of 2.75% convertible bonds due 2014 and convertible into fully paid and Managed Care rebates, partially offset by the decrease Ordinary Shares of Shire the Bonds.
The net proceeds of issuing in deferred revenue following the recognition into revenues in 2010 the Bonds, after deducting the commissions and other direct costs of INTUNIV Launch Stocks which previously had been deferred.
In connection with the 2008 Scheme of Arrangement the Trust Deed was amended and restated in order Other long-term debt to provide that, following the substitution of Shire in place of Old Shire Other long-term debt has decreased by $35.7 million to $7.9 million as the principal obligor and issuer of the Bonds, the Bonds would at December 31, 2010 December 31, 2009: $43.6 million, due be convertible into Ordinary Shares of Shire.
to the extinguishment of building finance obligations following the acquisition of LTP.
The Bonds were issued at 100% of their principal amount, and unless previously purchased and cancelled, redeemed or converted, will be redeemed on May 9, 2014 the Final Maturity Date at their principal amount.
8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 28 28 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Financial review The Bonds bear interest at 2.75% per annum, payable semi-annually Revolving credit facilities agreement in arrears on November 9 and May 9.
The Bonds constitute direct, On November 23, 2010 Shire entered into a committed multicurrency unconditional, unsubordinated and unsecured obligations of the revolving and swingline facilities agreement with a number of financial Company, and rank pari passu and ratably, without any preference institutions, for which Abbey National Treasury Services Plc trading as amongst themselves, and equally with all other existing and future Santander Global Banking and Markets, Bank of America Securities unsecured and unsubordinated obligations of the Company.
Limited, Barclays Capital, Citigroup Global Markets Limited, Lloyds TSB Bank plc and The Royal Bank of Scotland plc acted as mandated lead The Bonds may be redeemed at the option of the Company, at their arrangers and bookrunners the new RCF.
The new RCF is for an principal amount together with accrued and unpaid interest if: i at any aggregate amount of $1,200 million and cancelled Shires existing time after May 23, 2012 if on no less than 20 dealing days in any period committed revolving credit facility the old RCF.
The new RCF, which of 30 consecutive dealing days the value of Shires Ordinary Shares includes a $250 million swingline facility, may be used for general underlying each Bond in the principal amount of $100,000 would corporate purposes and matures on November 23, 2015. exceed $130,000: or ii at any time conversion rights have been exercised, and or purchases and corresponding cancellations, and or The interest rate on each loan drawn under the new RCF for each redemptions effected in respect of 85% or more in principal amount interest period is the percentage rate per annum which is the aggregate of Bonds originally issued.
The Bonds may also be redeemed at the of the applicable margin ranging from 0.90 to 2.25% per annum option of the Bond holder at their principal amount including accrued and LIBOR for the applicable currency and interest period.
Shire also but unpaid interest on May 9, 2012 the Put Option, or following the pays a commitment fee on undrawn amounts at 35% per annum occurrence of a change of control of Shire.
The Bonds are repayable of the applicable margin.
in US dollars, but also contain provisions entitling the Company to settle redemption amounts in Pounds sterling, or in the case of the Under the new RCF it is required that i Shires ratio of Net Debt to Final Maturity Date and following exercise of the Put Option, by EBITDA as defined within the new RCF agreement does not exceed delivery of the underlying Ordinary Shares and a cash top-up amount.
3.5:1 for either the 12 month period ending December 31 or June 30 unless Shire has exercised its option which is subject to certain The Bonds are convertible into Ordinary Shares during the conversion conditions to increase it to 4.0:1 for two consecutive testing dates: period, being the period from June 18, 2007 until the earlier of: i the ii the ratio of EBITDA to Net Interest as defined in the new RCF close of business on the date falling fourteen days prior to the Final agreement must not be less than 4.0:1, for either the 12 month period Maturity Date: ii if the Bonds have been called for redemption by the ending December 31 or June 30: and iii additional limitations on Company, the close of business fourteen days before the date fixed the creation of liens, disposal of assets, incurrence of indebtedness, for redemption: iii the close of business on the day prior to a Bond making of loans, giving of guarantees and granting security over assets.
holder giving notice of redemption in accordance with the conditions: and iv the giving of notice by the trustee that the Bonds are On entering into the new RCF agreement the Group paid arrangement accelerated by reason of the occurrence of an event of default.
costs of $8.0 million, which have been deferred and will be amortized over the contractual term of the new RCF.
Upon conversion, the Bond holder is entitled to receive Ordinary Shares at the conversion price of $33.17 per Ordinary Share, subject The availability of loans under the new RCF is subject to customary to adjustment as outlined below.
The conversion price is subject to adjustment in respect of i any Financing dividend or distribution by the Company, ii a change of control and Shire anticipates that its operating cash flow together with available iii customary anti-dilution adjustments for, inter alia, share cash, cash equivalents, restricted cash and the new RCF will be consolidations, share splits, spin-off events, rights issues, bonus sufficient to meet its anticipated future operating expenses, capital issues and re-organizations.
The initial conversion price of $33.5879 expenditures, tax and interest payments and lease obligations as was adjusted to $33.17 with effect from March 11, 2009 as a result they become due over the next twelve months.
of cumulative dividend payments during the period from October 2007 to April 2009 inclusive.
The Ordinary Shares issued on conversion If the Group decides to acquire other businesses, it expects to fund these will be delivered credited as fully paid, and will rank pari passu in all acquisitions from existing cash resources, the new RCF and possibly respects with all fully paid Ordinary Shares in issue on the relevant through new borrowings and the issue of new equity if necessary.
Review of our business 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 29 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 29 Sources and uses of cash of $326.6 million.
Capital expenditure on property, plant and The following table provides an analysis of the Groups gross and net equipment includes $121.9 million for the acquisition of new properties debt excluding restricted cash, as at December 31, 2010 and 2009: and properties previously occupied under operating leases and $134.5 million on construction work, at Lexington Technology Park.
2010 2009 December 31, $M $M Net cash used in investing activities was $322.4 million in the year to December 31, 2009.
This included the cash cost of purchasing Cash and cash equivalents 550.6 498.9 EQUASYM of $72.8 million and expenditure on property, plant and Shire 2.75% convertible bonds 1,100.0 1,100.0 equipment of $254.4 million.
These cash outflows were partially offset Building financing obligation 8.4 46.7 by receipts of $19.2 million from the sale of non-current investments.
Capital expenditure on property, plant and equipment included Total debt 1,108.4 1,146.7 $127.0 million on construction work at the HGT campus in Lexington, Net debt 557.8 647.8 Massachusetts, $18.4 million on construction work at the UK office in Basingstoke, Hampshire, and $19.9 million on infrastructure and Cash flow activity capital management projects in the US.
This capital expenditure Net cash provided by operating activities for the year to December 31, was funded from the Groups existing cash resources and operating 2010 increased by $328.0 million to $954.9 million 2009: $626.9 cash flows.
million, primarily due to higher cash receipts from product sales and royalties, cash inflows from forward foreign exchange contracts in 2010 Net cash used in financing activities was $99.5 million for the year to compared to outflows in 2009, partially offset by higher payments on December 31, 2010, including the dividend payment of $62.0 million sales deductions, operating costs and taxes in the year to December and $43.1 million to extinguish building finance obligations at Lexington 31, 2010 compared to the same period in 2009.
Net cash provided by operating activities for the year to December 31, Net cash used in financing activities was $28.7 million for the year 2009 decreased by 22% to $626.9 million compared to $800.1 million to December 31, 2009 which relates to $54.4 million for the dividend for the year to December 31, 2008, a decrease of $173.2 million.
Net payment partially offset by excess tax benefits of stock-based cash provided by operating activities was lower in 2009 compared to compensation of $16.8 million and proceeds from exercise of options 2008 due to lower net sales receipts and higher cash tax payments in of $14.6 million.
Net cash provided by operating activities in 2008 also included cash inflows on forward foreign exchange contracts Outstanding letters of credit which were not repeated in 2009.
These factors more than offset At December 31, 2010, the Group had irrevocable standby letters the inclusion of interest paid on settlement of the TKT appraisal rights of credit and guarantees with various banks totaling $24.3 million, in cash flow from operating activities in 2008. providing security for the Groups performance of various obligations.
These obligations are primarily in respect of the recoverability of Net cash used in investing activities was $797.4 million in the year to insurance claims, lease obligations and supply commitments.
This included the cash paid net of cash acquired Group has restricted cash of $9.2 million, as required by these letters of $449.6 million for, and payments of $33.4 million on foreign of credit.
exchange contracts related to, the acquisition of Movetis in October 2010, and expenditure on property, plant and equipment 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:26 Page 30 30 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Financial review Cash requirements At December 31, 2010 the Groups cash requirements for long-term liabilities reflected on the balance sheet and other contractual obligations were as follows: Payments due by period Less than More than Total 1 year 13 years 35 years 5 years $M $M $M $M $M 1 Long-term debt obligations 1,205.9 30.3 60.5 1,115.1 2 Operating leases obligation 150.2 34.2 41.7 35.3 39.0 3 Purchase obligations 450.6 335.8 108.8 6.0 4 Other long-term liabilities reflected on the balance sheet 167.3 7.0 156.9 1.3 2.1 Total 1,974.0 407.3 367.9 1,157.7 41.1 1 Shires $1,100 million principal amount of 2.75% convertible bonds due 2014 issued in May 2007 and the interest on the convertible bonds has been included based on the contractual payment dates.
The principal amount of $1,100 million has been included within payments due in three to five years based on the Final Maturity Date of the convertible bonds.
The bondholders have the option to redeem the convertible bonds at the principal amount in May 2012 and the Group has the option to call the bonds subject to certain conditions after May 2012.
Further details are included within Liquidity and capital resources: Shire 2.75% Convertible Bonds due 2014 above.
2 The Group leases certain land, facilities, motor vehicles and certain equipment under operating leases expiring through 2016.
3 Purchase obligations include agreements to purchase goods, investments or services including clinical trials, contract manufacturing and capital equipment that are enforceable and legally binding and that specify all significant terms, including open purchase orders.
Shire expects to fund these commitments with cash flows from operating activities.
4 Unrecognized tax benefits and associated interest and penalties of $6.5 million and $130.3 million are included within payments due in less than one year and payments due in one to three years, respectively.
The contractual obligations table above does not include certain Research collaboration with Santaris on Locked Nucleic Acid milestones and other contractual commitments where payment is LNA drug platform contingent upon the occurrence of events which are yet to occur On August 24, 2009 Shire announced that it had entered into and therefore payment is not yet due.
The most significant of the a research collaboration with Santaris, to develop its proprietary Groups milestone and contractual commitments which are contingent LNA technology in a range of rare diseases.
LNA technology has the on the occurrence of future events are as follows: benefit of shortened target validation and proof-of-concept, potentially increasing the speed and lowering the cost of development.
As part Collaboration with Acceleron for ActRIIB class of molecules of the joint research project Santaris will design, develop and deliver On September 9, 2010 Shire announced that it had expanded its pre-clinical LNA oligonucleotides for Shire-selected orphan disease HGT pipeline by acquiring an exclusive license in markets outside targets, and Shire will have the exclusive right to further develop and of North America for the ActRIIB class of molecules being developed commercialize these candidate compounds on a worldwide basis.
The collaboration will initially focus on further developing ACE-031, the lead ActRIIB drug candidate, which is in development In the year to December 31, 2009 Shire made an up-front payment for the treatment of patients with DMD.
The Phase 2a trial is on hold of $6.5 million to Santaris, for technology access and R&D funding, and clinical safety is under review.
ACE-031 and the other ActRIIB which has been expensed to R&D.
class of molecules have the potential to be used in other muscular and neuromuscular disorders with high unmet medical need.
In the year to December 31, 2010 Shire paid success milestones of $3.0 million.
Shire has remaining obligations to pay Santaris a further In the year to December 31, 2010 Shire made an up-front payment $10.5 million subject to certain success criteria, and development and of $45.0 million to Acceleron which has been expensed to R&D.
Shire sales milestones up to a maximum of $72.0 million for each indication.
will pay Acceleron up to a further $165.0 million, subject to certain Shire will also pay single or double-digit tiered royalties on net sales development, regulatory and sales milestones being met for ACE-031 of the product.
in DMD, up to an additional $288.0 million for successful commercialization of other indications and molecules, and royalties Shire and Santaris have formed a joint research committee to monitor on product sales.
R&D activities through pre-clinical Lead Candidate selection at which point all development and commercialization costs will be the Shire and Acceleron will conduct the collaboration through a joint responsibility of Shire.
steering committee, with subcommittees including a joint manufacture committee, and a joint patent committee to monitor the development of ACE-031 and other compounds.
Review of our business 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:27 Page 31 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 31 JUVISTA The Group may not be able to grow its product revenues as quickly On June 19, 2007 Shire signed an agreement with Renovo to develop as anticipated if any or all of the following occur: and commercialize JUVISTA, Renovos novel drug candidate being competitive products are genericized or if the prices of competitor investigated for the reduction of scarring in connection with surgery, products are otherwise reduced significantly, and the prescribing outside of the EU.
On March 1, 2010 the license agreement was revised.
of treatments for the indications that the Groups products treat is adversely affected: In the revised license agreement, the rights to sell JUVISTA in all territories outside the US, Mexico and Canada were returned tothere are unanticipated adverse events experienced with the Renovo.
Milestone and royalty obligations remain unchanged from the Groups products not seen in clinical trials that impact the physicians original agreement except that Shire will pay Renovo an additional willingness to prescribe the Groups products: $5 million milestone if Shire elects to commence a clinical trial following issues arise from clinical trials being conducted for post marketing Shires review of the clinical trial report from Renovos first EU Phase 3 purposes or for registration in another country or if regulatory clinical trial.
On February 11, 2011, Renovo announced that its Phase 3 agencies in one country act in a way that raises concerns for trial for JUVISTA in scar revision surgery did not meet its primary regulatory agencies or for prescribers or patients in another country: or secondary endpoints.
Shire is currently considering the trial data and whether to exercise its rights to terminate the license agreement.
patients, payors or physicians favor other treatments over the Groups products: Shire has remaining obligations to pay Renovo $25 million on the filing government regulation is stricter for the Groups products than of JUVISTA with the FDA: up to $150 million on FDA approval: royalties for other treatments: on net sales of JUVISTA: and up to $525 million on the achievement of very significant sales targets.
Under the revised agreement, each partyloss of patent protection or ability of competitors to challenge or is responsible for its own development costs but future development circumvent patents See Note 20 Commitments and contingencies costs can be shared by agreement.
Each party has free-of-charge to the consolidated financial statements for details of current patent access to the other partys data to support regulatory filings in their litigation : respective territories.
In the year to December 31, 2010 Shire made planned geographical expansion into emerging markets is not a payment to Renovo of $3.2 million 2009: $3.9 million, 2008: successful: $7.4 million, being the final payment under the terms of the original license agreement, which has been charged by Shire to R&D.
the size of the patient populations for the Groups products are less than expected or the Group fails to identify new patients for Principal risks and uncertainties its products: or The Group has adopted a risk management strategy designed to product liability claims.
identify, assess and manage the significant risks that it faces.
While the Group aims to identify and manage such risks, no risk management If the Group is unable to commercialize any of its key products strategy can provide absolute assurance against loss.
successfully, there may be a material adverse effect on the Groups revenues, financial condition and results of operations.
Set out below are the key risk factors, associated with the business, that have been identified through the Groups approach to risk In addition, the Group derives significant revenues and earnings management.
Some of these risk factors are specific to the Group, from mature portfolio products whether or not promoted including and others are more generally applicable to the pharmaceutical CARBATROL, CALCICHEW, REMINYL and XAGRID.
Sales of these industry in which the Group operates.
The Group considers that products could decrease as a result of any or all of the following: these risk factors apply equally and therefore all should be carefully considered before any investment is made in Shire.
if competitive products are genericized or if the prices of competitor products are otherwise reduced significantly, and the prescribing RISK FACTORS RELATED TO SHIRES BUSINESS of treatments for the indications that the Groups products treat is adversely affected: The Groups key products may not be a commercial success if there are unanticipated adverse events experienced with The commercial success of the Groups key productsELAPRASE, the Groups products not seen in clinical trials that impact the VYVANSE, LIALDA MEZAVANT, PENTASA, FOSRENOL, REPLAGAL, physicians willingness to prescribe the Groups products: INTUNIV, VPRIV, FIRAZYR and RESOLOR as well as other new products that the Group may launch in the future, will depend onif patients, payors or physicians favor other treatments over the their approval and acceptance by physicians, patients and other key Groups products: or decision-makers, as well as the timing of the receipt of additional if the Groups products suffer a loss of patent protection or marketing approvals, the scope of marketing approvals as reflected competitors successfully challenge or circumvent the Groups in the products label, the countries in which such approvals are patents or regulatory exclusivity See Note 20 Commitments and obtained, the authorization of price and reimbursement in those contingencies to the consolidated financial statements for details countries where price and reimbursement are negotiated, and safety, of current patent litigation.
efficacy, convenience and cost-effectiveness of the product as compared to competitive products.
8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:27 Page 32 32 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Financial review Unanticipated decreases in revenues from ADDERALL XR The failure to obtain and maintain reimbursement, or could significantly reduce the Groups revenues and earnings an adequate level of reimbursement, by third-party payors In the year to December 31, 2010 sales of ADDERALL XR declined in a timely manner for the Groups products may impact 42% to $360.8 million, representing approximately 10% of the Groups future revenues and earnings total revenues, sales of ADDERALL XR in the years to December 31, The Groups revenues are partly dependent on the level of 2009 and 2008 were $626.5 million and $1,101.7 million respectively.
reimbursement provided to the Group by governmental reimbursement This decline resulted directly from the launch by Teva and Impax schemes for pharmaceutical products.
Changes to governmental of authorized generic versions of ADDERALL XR in April and October policy or practices could adversely affect the Groups revenues, financial 2009, respectively.
The Group sells the authorized generic version condition and results of operations.
In addition, the reimbursement of ADDERALL XR to Teva and Impax and currently receives royalties of treatment established by healthcare providers, private health insurers from Impax on the sale of its authorized generic.
Shire continues to and other organizations, such as health maintenance organizations sell the branded version of ADDERALL XR.
and managed care organizations are under downward pressure and this, in turn, could impact on the prices at which the Group can sell Factors that could negatively impact total revenue from ADDERALL XR its products.
include, but are not limited to: The market for pharmaceutical products could be significantly faster than anticipated erosion of ADDERALL XR sales and influenced by the following, which could result in lower prices for the elimination of the Impax royalty as a result of FDA approval Groups products and or a reduced demand for the Groups products: of additional generic competitors: issues impacting the production of ADDERALL XR or the supply the ongoing trend toward managed healthcare, particularly in the US: of amphetamine salts including, but not limited to, the ability to get sufficient quota from the US DEA:legislative proposals to reform healthcare and government insurance programs in many of the Groups markets: and changes in reimbursement policies of third-party payors: and changes to the level of sales deductions for ADDERALL XR price controls and non-reimbursement of new and highly priced for private or public payors.
medicines for which the economic and therapeutic rationales are not established.
In addition, in respect of the period prior to October 1, 2010, when certain provisions of the 2010 Affordable Care Act became The prices for certain of the Groups products when commercialized, effective and provided further clarity, there were potentially different in particular products for the treatment of rare genetic diseases such interpretations as to how shipments of authorized generic ADDERALL as REPLAGAL, ELAPRASE and VPRIV, may be high compared to XR to Teva and Impax should be included in the Medicaid rebate other pharmaceutical products.
The Group may encounter particular calculation.
The CMS may disagree with the Groups interpretation difficulty in obtaining satisfactory pricing and reimbursement for its as to how shipments of authorized generic ADDERALL XR should be products, particularly those with a high cost of treatment.
The failure included in the Medicaid rebate calculation, require the Group to apply to obtain and maintain pricing and reimbursement at satisfactory levels an alternative interpretation of the Medicaid rebate legislation and pay for such products may adversely affect the Groups revenues, financial an additional amount in excess of the liability recorded by the Group.
condition and results of operations.
Any decrease in royalties derived from the sales of 3TC A disruption to the product supply chain may result in and ZEFFIX could significantly reduce earnings the Group being unable to continue marketing or developing The Group receives royalties from GSK on the worldwide sales of a product or may result in the Group being unable to do 3TC and ZEFFIX.
In 2010, the Groups royalty income relating to 3TC so on a commercially viable basis and ZEFFIX sales was $154.0 million 2009: $164.0 million: 2008: The Group sources its products from third-party contract manufacturers, $180.5 million.
Any factors that decrease sales of 3TC and ZEFFIX and for certain products has its own manufacturing capability.
In the by GSK could significantly reduce the Groups royalty revenue, event of either the Groups failure or the failure of any third-party contract and negatively affect results of operations.
These include, but are not manufacturer to comply with mandatory manufacturing standards often limited to: referred to as Current Good Manufacturing Standards or cGMP in the countries in which the Group sells or intends to sell or have its products loss of patent protection or ability of competitors to challenge sold or suffering another form of disruption to the supply chain, or circumvent patents See Note 20 Commitments and the Group may experience a delay in supply or be unable to market contingencies to the consolidated financial statements for details or develop its products.
of current patent litigation : reduction in the production of 3TC and ZEFFIX: The Group dual-sources certain key products and or active ingredients.
However, the Group currently relies on a single source technological advances: for production of the final drug product for each of ADDERALL XR, government action intervention: FOSRENOL, FIRAZYR, INTUNIV, CARBATROL, PENTASA, VPRIV, RESOLOR and XAGRID and relies on a single active ingredient source public opinion towards AIDS treatments: and for each of ELAPRASE, FIRAZYR, FOSRENOL, REMINYL, REPLAGAL, product liability claims.
Review of our business 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:27 Page 33 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 33 In the event of financial failure of a third-party contract manufacturer or Investigations or enforcement action by regulatory authorities the failure of the third-party manufacturer to comply with its contractual or law enforcement agencies relating to the Groups activities obligations, the Group may experience a delay in supply or be unable in the highly regulated markets in which it operates may result to market or develop its products.
This could have a material adverse in the distraction of senior management, significant legal affect on the Groups financial condition and results of operations.
costs and the payment of substantial compensation or fines The Group engages in various marketing, promotional and educational There is no assurance that suppliers will continue to supply on activities pertaining to, as well as the sale of, pharmaceutical commercially viable terms, or be able to supply components that products in a number of jurisdictions around the world.
The promotion, meet regulatory requirements.
The Group is also subject to the marketing and sale of pharmaceutical products is highly regulated and risk that suppliers will not be able to meet the quantities needed the operations of market participants, such as the Group, are closely to meet market requirements which may result in the shortage supervised by regulatory authorities and law enforcement agencies, of product supplies in the market including the US Department of Health and Human Services HHS, The development and approval of the Groups products depend on the FDA, the US Department of Justice and the DEA in the US.
the ability to procure active ingredients and special packaging materials Any inquiries or investigations into the operations of, or enforcement from sources approved by regulatory authorities.
As the marketing or other regulatory action against, the Group by such regulatory approval process requires manufacturers to specify their own proposed authorities could result in the distraction of senior management for suppliers of active ingredients and special packaging materials in their prolonged periods of time, significant defence costs, substantial applications, regulatory approval of a new supplier would be required monetary penalties and require extensive government monitoring if active ingredients or such packaging materials were no longer of Group activities in the future.
As an example, on September 23, available from the supplier specified in the marketing approval.
The 2009 the Group received a subpoena from the HHS Office of Inspector need to qualify a new supplier could delay the Groups development General in coordination with the US Attorney for the Eastern District and commercialization efforts.
of Pennsylvania, seeking production of documents related to the sales and marketing of ADDERALL XR, VYVANSE and DAYTRANA.
Shire The Group uses bovine-derived serum sourced from New Zealand is cooperating and responding to this subpoena.
and North America in the manufacturing process for ELAPRASE.
The discovery of additional cattle in North America or the discovery The outsourcing of services can create a significant of cattle in New Zealand with bovine spongiform encephalopathy, dependency on third-parties, the failure of whom can affect or mad cow disease, could cause the regulatory agencies in some the ability to operate the Groups business and to develop countries to impose restrictions on these products, or prohibit the and market products Group from using these products at all in such countries.
The Group has entered into many agreements with third-parties for the provision of services to enable it to operate its business.
The actions of certain customers can affect the Groups ability If the third-party can no longer provide the service on the agreed to sell or market products profitably, as well as impact net sales basis, the Group may not be able to continue the development or and growth comparisons commercialization of its products as planned or on a commercial A small number of large wholesale distributors control a significant basis.
Additionally, it may not be able to establish or maintain good share of the US and certain European markets.
In 2010, for example, relationships with the suppliers.
44% of the Groups product sales were attributable to two customers in the US: McKesson Corp. and Cardinal Health, Inc.
In the event of The Group has also entered into licensing and co-development financial failure of any of these customers, the Group may suffer agreements with a number of parties.
There is a risk that, upon financial loss and a decline in revenues and earnings.
In addition, the expiration or termination of a third-party agreement, the Group may number of independent drug stores and small chains has decreased not be able to renew or extend the agreement with the third-party as retail pharmacy consolidation has occurred.
Consolidation or as commercial interests may no longer coincide.
In such financial difficulties could cause customers to reduce their inventory circumstances, the Group may be unable to continue to develop levels, or otherwise reduce purchases of the Groups products.
Such or market its products as planned and could be required to abandon actions could have an adverse effect on the Groups revenues, financial or divest a product line.
A significant portion of the Groups SP product sales are made to major pharmaceutical wholesale distributors as well as to large pharmacies in both the US and Europe.
Consequently, product sales and growth comparisons may be affected by fluctuations in the buying patterns of major distributors and other trade buyers.
These fluctuations may result from seasonality, pricing, wholesaler buying decisions, or other factors.
In addition, a significant portion of the Groups revenues for certain products for treatment of rare genetic diseases are concentrated with a small number of customers.
Changes in the buying patterns of those customers may have an adverse effect on the Groups revenues, financial condition and results of operations.
8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:27 Page 34 34 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Financial review RISK FACTORS RELATED TO THE PHARMACEUTICAL Success in pre-clinical and early clinical trials does not ensure that INDUSTRY IN GENERAL large-scale clinical trials will be successful.
Clinical results are frequently susceptible to varying interpretations that may delay, limit, or prevent The actions of governments, industry regulators and the regulatory approvals.
The length of time necessary to complete clinical economic environments in which the Group operates may trials and to submit an application for marketing approval for a final adversely affect its ability to develop and market its products decision by a regulatory authority varies significantly and may be profitably difficult to predict.
If the Groups large-scale or late state clinical trials Changes to laws or regulations impacting the pharmaceutical industry, for a product are not successful, the Group will not recover its in any country in which the Group conducts its business, may substantial investments in that product.
adversely impact the Groups revenues, financial condition and results of operations.
In particular, changes to the regulations relating to In addition, even if the products receive regulatory approval, they orphan drug status may affect the exclusivity granted to products remain subject to ongoing regulatory requirements, including, with such designation.
for example, obligations to conduct additional clinical trials or other non-clinical testing, changes to the product label, new or revised The introduction of new products by competitors may impact requirements for manufacturing, written notifications to physicians, future revenues or product recalls or withdrawals.
Further, a number of the Groups The manufacture and sale of pharmaceuticals is highly competitive.
products that treat ADHD contain controlled substances and are Many of the Groups competitors are large, well-known subject to regulation by the US DEA and equivalent agencies in pharmaceutical, biotechnology, chemical and healthcare companies other countries.
Companies with more resources and larger R&D expenditures have a greater ability to fund clinical trials and The failure of a strategic partner to develop and commercialize other development work necessary for regulatory applications.
They products could result in delays in approval or loss of revenue may also be more successful than the Group in acquiring or licensing The Group enters into strategic partnerships with other companies new products for development and commercialization.
If any product in areas such as product development and sales and marketing.
In that competes with one of the Groups principal drugs is approved, these partnerships, the Group is sometimes dependent on its partner the Groups sales of that drug could fall.
While these partnerships are supported by contracts, the Group may not exercise direct control.
If a partner fails to perform The pharmaceutical and biotechnology industries are also characterized or experiences financial difficulties, the Group may suffer a delay by continuous product development and technological change.
in the development, a delay in the approval or a reduction in sales The Groups products could, therefore, be rendered obsolete or or royalties of a product.
uneconomical, through the development of new products, technological advances in manufacturing or production by its competitors.
The failure to secure new products or compounds for development, either through in-licensing, acquisition The successful development of pharmaceutical products is or internal research and development efforts, may have highly uncertain and requires significant expenditures and time an adverse impact on the Groups future results Products that appear promising in research or development may The Groups future results will depend, to a significant extent, upon its be delayed or fail to reach later stages of development or the market ability to in-license, acquire or develop new products or compounds.
for several reasons, including: The Group also expends significant resources on research and development.
The failure to in-license or acquire new products or pre-clinical or clinical tests may show the product to lack safety compounds, on a commercially viable basis, could have a material or efficacy: adverse effect on the Groups revenues, financial condition and results delays may be caused by slow enrollment in clinical studies: of operations.
The failure of these efforts to result in the development additional clinical supplies requirements: extended length of time of products appropriate for testing in human clinical trials could have to achieve study endpoints: additional time requirements for data a material adverse effect on the Groups revenues, financial condition analysis or dossier preparation: discussions with regulatory agencies, and results of operations.
including regulatory agency requests for additional pre-clinical or clinical data: delays at regulatory agencies due to staffing or The Group may fail to obtain, maintain, enforce or defend the resource limitations: analysis of or changes to study design: intellectual property rights required to conduct its business unexpected safety, efficacy, or manufacturing issues.
Delays The Groups success depends upon its ability and the ability of its may arise from shared control with collaborative partners in the partners and licensors to protect their intellectual property rights.
planning and execution of the product development, scaling of Where possible, the Groups strategy is to register intellectual property the manufacturing process, or getting approval for manufacturing: rights, such as patents and trademarks.
The Group also relies variously on trade secrets, unpatented know-how and technological manufacturing issues, pricing, reimbursement issues, or other innovations and contractual arrangements with third-parties to factors may render the product economically unviable: maintain its competitive position.
the proprietary rights of others and their competing products and technologies may prevent the product from being developed or commercialized: and failure to receive necessary regulatory approvals.
Review of our business 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:27 Page 35 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 35 Patents and patent applications covering a number of the technologies If a marketed product fails to work effectively or causes adverse and processes owned or licensed to the Group have been granted, side-effects, this could result in damage to the Groups reputation, or are pending in various countries, including the US, Canada, major the withdrawal of the product and legal action against the Group European countries and Japan.
The Group intends to enforce Unanticipated side-effects or unfavorable publicity from complaints vigorously its patent rights and believes that its partners intend to concerning any of the Groups products, or those of its competitors, enforce vigorously patent rights they have licensed to the Group.
could have an adverse effect on the Groups ability to obtain or However, patent rights may not prevent other entities from developing, maintain regulatory approvals or successfully market its products.
using or commercializing products that are similar or functionally The testing, manufacturing, marketing and sales of pharmaceutical equivalent to the Groups products or technologies.
The Groups patent products entails a risk of product liability claims, product recalls, rights may be successfully challenged in the future or laws providing litigation and associated adverse publicity.
The cost of defending such rights may be changed or withdrawn.
The Group cannot assure against such claims is expensive even when the claims are not merited.
investors that its patents and patent applications or those of its thirdA successful product liability claim against the Group could require party manufacturers will provide valid patent protection sufficiently the Group to pay a substantial monetary award.
If, in the absence broad to protect the Groups products and technology or that such of adequate insurance coverage, the Group does not have sufficient patents will not be challenged, revoked, invalidated, infringed or financial resources to satisfy a liability resulting from such a claim or circumvented by third-parties.
In the regular course of business, the to fund the legal defense of such a claim, it could become insolvent.
Group is party to litigation or other proceedings relating to intellectual Product liability insurance coverage is expensive, difficult to obtain and property rights.
See Note 20 Commitments and contingencies to the may not be available in the future on acceptable terms.
Although the consolidated financial statements for details of current patent litigation.
Group carries product liability insurance when available, this coverage may not be adequate.
In addition, it cannot be certain that insurance Additionally, the Groups products, or the technologies or processes coverage for present or future products will be available.
Moreover, an used to formulate or manufacture those products may now, or in the adverse judgement in a product liability suit, even if insured or future, infringe the patent rights of third-parties.
It is also possible that eventually overturned on appeal, could generate substantial negative third-parties will obtain patent or other proprietary rights that might publicity about the Groups products and business and inhibit or be necessary or useful for the development, manufacture or sale of prevent commercialization of other products.
If third-parties are the first to invent a particular product or technology, it is possible that those parties will obtain Loss of highly qualified management and scientific personnel patent rights that will be sufficiently broad to prevent the Group could cause the Group subsequent financial loss or its strategic partners from developing, manufacturing or selling The Group faces competition for highly qualified management and its products.
The Group may need to obtain licenses for intellectual scientific personnel from other companies, academic institutions, property rights from others to develop, manufacture and market government entities and other organizations.
It may not be able commercially viable products and may not be able to obtain these to successfully attract and retain such personnel.
The Group has licenses on commercially reasonable terms, if at all.
In addition, any agreements with a number of its key scientific and management licensed patents or proprietary rights may not be valid and enforceable.
personnel for periods of one year or less.
The loss of such personnel, or the inability to attract and retain the additional, highly skilled The Group also relies on trade secrets and other un-patented employees required for its activities could have an adverse effect proprietary information, which it generally seeks to protect by on the Groups business.
confidentiality and nondisclosure agreements with its employees, consultants, advisors and partners.
These agreements may not Mitigation of principal risks effectively prevent disclosure of confidential information and may The management and mitigation of the above mentioned risks are not provide the Group with an adequate remedy in the event of a key focus for the Group.
The Risk Council has been established to unauthorized disclosure of such information.
If the Groups employees, oversee the management and mitigation of the principal risks faced scientific consultants or partners develop inventions or processes by the Group, as set out above.
The Risk Council comprises a cross that may be applicable to the Groups products under development, functional group of senior executives chaired by the Chief Compliance such inventions and processes will not necessarily become the and Risk Officer.
Material risks are recorded twice a year on a Groups property, but may remain the property of those persons or corporate risk schedule the Schedule which allocates specific their employers.
Protracted and costly litigation could be necessary mitigation or management responsibility to senior management, to enforce and determine the scope of the Groups proprietary rights.
and is reviewed by both the Leadership Team and the Risk Council.
The failure to obtain or maintain patent and trade secret protection, The items on the Schedule considered by the Risk Council to for any reason, could allow other companies to make competing constitute areas of higher risk were also reviewed by the Audit, products and reduce the Groups product sales.
Compliance & Risk Committee and the Board of Directors.
The Group has filed applications to register various trademarks for use in connection with its products in various countries including the US and countries in Europe and Latin America and intends to trademark new product names as new products are developed.
In addition, with respect to certain products, the Group relies on the trademarks of third-parties.
These trademarks may not afford adequate protection or the Group or the third-parties may not have the financial resources to enforce any rights under any of these trademarks.
The Groups inability or the inability of these third-parties to protect their trademarks because of successful third-party claims to those trademarks could allow others to use the Groups trademarks and dilute their value.
8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:27 Page 36 36 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Financial review Treasury policies and organization Transactional exposure arises where transactions occur in currencies The Groups principal treasury operations are co-ordinated by its different to the functional currency of the relevant subsidiary.
The main corporate treasury function.
All treasury operations are conducted trading currencies of the Group are the US dollar, the Canadian dollar, within a framework of policies and procedures approved annually by Pound sterling and the Euro.
It is the Groups policy that these the Board of Directors the Board.
As a matter of policy, the Group exposures are minimized to the extent practicable by denominating does not undertake speculative transactions that would increase its transactions in the subsidiarys functional currency.
currency or interest rate exposure.
Where significant exposures remain, the Group uses foreign exchange Interest rate risk contracts being spot, forward and swap contracts to manage the The Group is exposed to interest rate risk on restricted cash, cash and exposure for balance sheet assets and liabilities that are denominated cash equivalents and on foreign exchange contracts on which interest in currencies different to the functional currency of the relevant is at floating rates.
This exposure is primarily to US dollar, Canadian subsidiary.
These assets and liabilities relate predominantly to interdollar, Pound sterling and Euro interest rates.
As the Group maintains company financing and accruals for royalty receipts.
The foreign all of its cash, liquid investments and foreign exchange contracts on a exchange contracts have not been designated as hedging instruments.
short-term basis for liquidity purposes, this risk is not actively managed.
Cash flows from derivative instruments are presented within net cash In the year to December 31, 2010 the average interest rate received on provided by operating activities in the consolidated cash flow cash and liquid investments was less than 1% per annum.
The largest statement, unless the derivative instruments are economically hedging proportion of these cash and liquid investments was in US dollar specific investing or financing activities such as restricted cash held money market and liquidity funds.
in respect of the purchase price of Movetis.
The Group incurs interest at a fixed rate of 2.75% on Shire $1,100 million Translational foreign exchange exposure arises on the translation in principal convertible bonds due 2014. into US dollars of the financial statements of non-US dollar functional subsidiaries.
No derivative instruments were entered into during the year to December 31, 2010 to manage interest rate exposure.
The Group At December 31, 2010 the Group had 31 swap and forward foreign continues to review its interest rate risk and the policies in place to exchange contracts outstanding to manage currency risk.
The swaps manage the risk.
and forward contracts mature within 90 days.
The Group did not have credit risk related contingent features or collateral linked to the Foreign exchange risk derivatives.
At December 31, 2010 the fair value of these contracts The Group trades in numerous countries and as a consequence has was a net asset of $1.0 million.
Further details are included below.
transactional and translational foreign exchange exposure.
Foreign exchange risk sensitivity The table below provides information about the Groups swap and forward foreign exchange contracts by currency pair.
The table presents the net principal amounts and weighted-average exchange rates of all outstanding contracts.
All contracts have a maturity date of less than three months.
Principal Weightedvalue of average amount exchange receivable rate Fair value December 31, 2010 $M $M Swap foreign exchange contracts Receive USD Pay EUR 20.0 1.50 2.0 Receive GBP Pay USD 109.2 1.60 1.6 Receive CAD Pay USD 78.0 0.99 0.8 Receive USD Pay SEK 2.6 6.84 Receive USD Pay AUD 3.6 1.02 0.1 Receive USD Pay CHF 2.7 1.05 0.1 Review of our business 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:27 Page 37 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 37 Market risk of investments Inflation As at December 31, 2010 the Group has $101.6 million of investments Although at reduced levels in recent years, inflation continues to apply comprising available-for-sale investments in publicly quoted companies upward pressure on the cost of goods and services which are used $83.9 million, equity-method investments $11.8 million and cost in the business.
However, the Group believes that the net effect of method investments in private companies $5.9 million.
The investment inflation on its revenues and operations has been minimal during the in publicly-quoted companies and equity-method investments in past three years.
respect of certain investment funds which contain a mixed portfolio of public and private investments are exposed to market risk.
No financial Dividend policy instruments or derivatives have been employed to hedge this risk.
A first interim dividend for the first half of 2010 of 2.25 US cents 1.41 pence per Ordinary Share, equivalent to 6.75 US cents per Credit risk ADS, was paid in October 2010.
The Board has resolved to pay a Financial instruments that potentially expose Shire to concentrations second interim dividend of 10.85 US cents 6.73 pence per Ordinary of credit risk consist primarily of short-term cash investments, trade Share equivalent to 32.55 US cents per ADS for the six months to accounts receivable from product sales and royalty receipts and December 31, 2010. derivative contracts.
Shire has cash invested in short-term money market instruments, including money market and liquidity funds and A first interim dividend for the first half of 2009 of 2.147 US cents bank term deposits.
The money market and liquidity funds in which 1.302 pence per Ordinary Share, equivalent to 6.441 US cents per Shire invests are all triple A rated by both Standard & Poors and by ADS, was paid in October 2009.
A second interim dividend for the Moodys credit rating agencies.
second half of 2009 of 9.250 US cents 5.910 pence per Ordinary Share equivalent to 27.750 US cents per ADS was paid in April 2010.
The Group is exposed to the credit risk of the counterparties with which it enters into derivative contracts.
The Group aims to limit This is consistent with Shires stated policy of paying a dividend semithis exposure through a system of internal credit limits which require annually, set in US cents per Ordinary Share.
Typically, the first interim counterparties to have a long-term credit rating of A A2 or better payment each year will be the higher of the previous years first interim from the major rating agencies.
The internal credit limits are approved USD dividend and the USD equivalent of the previous years first by the Board and exposure against these limits is monitored by the interim GBP dividend.
Dividend growth for the full year will be reviewed corporate treasury function.
The counterparties to the derivative by the Board when the second interim dividend is determined.
contracts are major international financial institutions.
Any dividend growth will come through increasing the second interim dividend in a financial year.
The Groups revenues from product sales are mainly governed by agreements with major pharmaceutical wholesalers and relationships with other pharmaceutical distributors and retail pharmacy chains.
For the year to December 31, 2010 there were two customers in the US who accounted for 44% of the Groups product sales.
However, such customers typically have significant cash resources and as such the Graham Hetherington risk from concentration of credit is considered minimal.
The Group has Chief Financial Officer taken positive steps to manage any credit risk associated with these transactions and operates clearly defined credit evaluation procedures.
Off-balance sheet arrangements There are no off-balance sheet arrangements aside from the milestone payments mentioned above that have, or are reasonably likely to have, a current or future effect on the Groups financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.
